Improvement Opportunities in the Multimodal Treatment of Pediatric Brain Tumors by Rojas de Pablo, Teresa de
UNIVERSIDAD AUTÓNOMA DE MADRID 
 
FACULTAD DE MEDICINA 
 
 
 
 
 
 
 
IMPROVEMENT OPPORTUNITIES 
IN THE MULTIMODAL TREATMENT 
OF PEDIATRIC BRAIN TUMORS 
 
 
 
 
 
 
TESIS DOCTORAL DE: 
TERESA DE ROJAS DE PABLO 
 
 
BAJO LA DIRECCIÓN DE: 
DR. LUCAS MORENO MARTÍN-RETORTILLO 
 
 
 
 
Madrid, 2018 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
6 
El presente trabajo de investigación ha sido realizado en el Servicio de 
Hemato-Oncología Pediátrica del Hospital Infantil Universitario Niño Jesús, 
Madrid, con la colaboración del grupo de tumores del sistema nervioso central 
de la Sociedad Española de Hematología y Oncología Pediátricas (SEHOP), así 
como en el EORTC (European Organisation for Research and Treatment of 
Cancer), Bruselas, Bélgica. 
 
 
 
Durante la realización de esta tesis, Teresa de Rojas de Pablo ha recibido 
financiación de la Fundación Caico (Beca Willis) y de Fonds Cancer (fellowship 
de investigación clínica en el EORTC), y ha trabajado también como médico 
adjunto en Oncología Pediátrica en el Hospital Infantil Universitario Niño 
Jesús, Madrid, España. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
7 
 
 
 
 
A Isabel, siempre 
 
A mi abuela, la mejor del mundo mundial 
 
Für Sarah, weil mit ihr kein Drache jemals zu groß war 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
9 
ACKNOWLEDGMENTS 
 
 
 
 
 
 
 
 
 
 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
11 
- To Lucas Moreno, for his mentorship and friendship, for making me fall in 
love with Clinical Research, for his endless patience, his acid humor and his 
huge heart, for his passion for Science, and for his inspiring pursue of 
excellence 
- To Luis Madero, for his trust in me, for giving me the opportunity and the 
freedom to pursue a research career 
- To Paco Bautista, my other mentor and friend, for his thoroughness and his 
infinite kindness, for being by my side during my first steps in the field of 
pediatric oncology, and for supporting me ever since 
- To the FIB-HNJ Clinical Trials Unit team, for helping me grow as a 
researcher and for their enormous contribution to curing childhood cancer 
- To the EORTC and all my colleagues, for letting me be part of this noble 
ship and its mission of curing cancer, and for providing me with both 
freedom and support to thrive and build new research projects 
- To Rosana Muñoz, Julia Cano, Pilar Brañas, Miriam Gª Abós, Ester Sanz, 
Dorita Blanco, Pilar Herreros, and so many other incredible pediatricians 
and pediatric nurses, for leading my way throughout this beautiful specialty 
- To my university professors, José Ramón Sañudo, Ángeles Vicente, 
Francisco Mora and Pedro Gª Barreno, for waking up in me and nourishing 
my love for Medical Science 
- To my sister Isabel and to my friends, Sarah, Vicky, Alba, Héctor, Mitsumi, 
Keita, Michal, Hafida, Jaques, Marina, Luna, Ángela, Pili, Serpil, Aylin, Mar, 
Álex, Bea, Jose, Esther, Ana, Paula, and the ones I might be forgetting, for 
their love throughout time and space; “You always took me with a smile 
when I was down”… 
- To the children, for being the most precious thing in this crazy planet of 
ours, in the hope I will never forget the lines of that song: “Y recuerda que 
un día dijiste: de grande no quisiera ser mayor…” 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
13 
INDEX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
15 
ABBREVIATIONS …………………………………………………………… 
 
19 
SUMMARY …………………………………………………………………… 
RESUMEN EN ESPAÑOL ………………………………………………….. 
 
23 
27 
I. INTRODUCTION ………………………………………………………..... 
1. Primary malignant CNS tumors in childhood 
2. CNS embryonal tumors 
2.1. Medulloblastoma 
2.2. Non-medulloblastoma CNS embryonal tumors (former 
PNET) 
3. Clinical trials versus real-world data 
4. Clinical audit and quality assurance 
5. Context of the research projects 
 
31 
33 
34 
 
 
 
45 
47 
49 
 
II. HYPOTHESES AND OBJECTIVES ………………………….…………. 
1. Aims 
2. Hypotheses 
3. Objectives 
 
51 
III. RESEARCH PROJECT #1 …………………………………….………... 
1. Introduction 
2. Methods 
2.1.  Patient identification 
2.2.  Eligibility 
2.3.  Record review 
2.4.  Statistical analysis 
3. Results 
57 
59 
61 
 
 
 
 
66 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
16 
3.1.  Patient demographics and presentation 
3.2.  Biological features 
3.3.  Referral pathway 
3.4.  First line treatment 
3.4.1. Global strategy 
3.4.2. Surgery 
3.4.3. Radiotherapy 
3.4.4. Chemotherapy 
3.4.5. Autologous HSCT 
3.5.  Toxic mortality and second malignancies 
3.6.  Relapse and patterns of failure 
3.7.  Salvage treatment on first relapse 
3.8.  Outcomes and prognostic factors 
3.9.  Time-related indicators across different frontline 
treatment milestones 
3.10. Post-end of treatment toxicities / Sequelae 
3.11. Improvement opportunities and quality assurance 
4. Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
IV. RESEARCH PROJECT #2 ……………..……………………………..… 
1. Introduction 
2. Methods 
2.1.  Patient identification 
2.2.  Eligibility 
2.3.  Record review 
2.4.  Statistical analysis 
3. Results 
3.1.  Patient demographics and presentation 
97 
99 
100 
 
 
 
 
103 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
17 
3.2.  Biological features 
3.3. First line treatment 
3.3.1. Global strategy 
3.3.2. Surgery 
3.3.3. Radiotherapy 
3.3.4. Chemotherapy 
3.3.5. Autologous HSCT 
3.4.  Toxic mortality 
3.5.  Relapse and patterns of failure 
3.6.  Salvage treatment on first relapse 
3.7.  Outcomes and prognostic factors 
3.8.  Neurocognitive outcome 
4. Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
V. RESEARCH PROJECT #3 ………………………………..…………..…. 
1. Introduction 
2. Past and present 
2.1.  Current status of RTQA in pediatric CNS tumors in Europe 
2.2.  Survey: Current practices of radiation oncologists across 
Europe 
2.2.1. Methodology 
2.2.2. Results 
3. Future 
3.1.  First steps and future development 
3.2.  What is the dream? Identified areas of improvement 
 
119 
121 
123 
 
 
 
 
 
140 
 
 
 
VI. DISCUSSION …………………………………..………………………... 
 
149 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
18 
VII. CONCLUSIONS ………………………………..……………………..... 
CONCLUSIONES EN ESPAÑOL ………………………………………..… 
 
159 
163 
 
VIII. APPENDICES ………………………………………………………...... 
1. Appendix 1: Survey questionnaire 
 
167 
169 
 
IX. REFERENCES ………………………..…………………………………... 
 
171 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
19 
ABBREVIATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
21 
aHSCT Autologous Hematopoietic Stem Cell Transplantation 
ATRT Atypical Teratoid Rhabdoid Tumor 
CI Confidence Interval 
CNS Central Nervous System 
COG Children’s Oncology Group 
CSI Craniospinal Irradiation 
CT Chemotherapy 
CTCAE Common Terminology Criteria for Adverse Events 
EORTC European Organisation for Research and Treatment of 
Cancer 
ET Embryonal Tumors 
ETANTR Embryonal Tumor with Abundant Neuropil and True 
Rosettes 
ETMR Embryonal Tumor with Multilayered Rosettes 
GTR Gross Total Resection 
HART Hyperfractionated Accelerated RadioTherapy 
HNJ Hospital Niño Jesús, Madrid 
HR High Risk 
IMRT Intensity Modulated Radiation Therapy 
MRI Magnetic Resonance Imaging 
NCI National Cancer Institute 
NTCP Normal Tissue Complication Probability 
OS Overall Survival 
PB Pineoblastoma 
PFS Progression Free Survival 
PNET Primitive NeuroEctodermal Tumors 
PT Particle Therapy 
QA Quality Assurance 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
22 
QI Quality Indicator 
QOL Quality Of Life 
QUARTET QUAlity and excellence in RadioTherapy and imaging 
for children and adolescents with cancer across Europe 
in clinical Trials 
RCT Randomized Clinical Trial 
RT Radiotherapy 
RTQA Radiotherapy Quality Assurance 
SEHOP Spanish Society of Pediatric Hematology and Oncology 
SHH Sonic Hedgehog 
SIOPe European Society of Pediatric Oncology 
SR Standard Risk 
STR Subtotal Resection 
WHO World Health Organization 
WNT Wingless 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
23 
SUMMARY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
25 
The treatment of pediatric CNS tumors remains one of the major 
challenges in modern pediatric oncology. The general aim of this study is to 
improve the management of these patients, on a multilevel approach: At an 
institutional/local, national and international/European level. Three research 
projects were carried out:  
In Research Project #1, a monocentric review of all pediatric patients 
with medulloblastoma treated between 2003 and 2016 at Hospital Niño Jesús, 
Madrid, was performed. While the global outcome of the 58 included patients 
was similar to the outcome observed in European population-based studies (5-
year OS: 59%), several measures were proposed to improve the identified 
weak areas. These measures include implementing a quality assurance system, 
promoting the inclusion in international clinical trials, establishing a central 
pathology review, accelerating the translation of the new molecular knowledge 
into daily practice, and implementing a neurocognitive and QOL evaluation 
program. Moreover, a set of 27 quality indicators to evaluate the management 
of these patients was developed. 
In Research Project #2, all pediatric patients with non-medulloblastoma 
CNS embryonal tumors treated in eight major oncology centers in Spain 
between 2005 and 2014 were reviewed. The 43 included patients presented a 
dismal outcome (3-year OS: 35%), especially when compared to patients 
included in clinical trials. Establishing a common national strategy, 
implementing referral circuits and collaboration networks, and incorporating 
new molecular knowledge into routine clinical practice were proposed as 
accessible measures that can improve the outcome of these patients. 
Additionally, a retrospective molecular analysis (methylation profiling) of tumor 
samples of this patient cohort was started. 
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In Research Project #3, the radiotherapy quality assurance (RTQA) 
systems in past and current clinical trials protocols for pediatric CNS tumors 
were analyzed. Several initiatives to implement RTQA, both at national and 
international levels, are being developed across Europe. Furthermore, a survey 
about the practices of RTQA in pediatric CNS tumors across 21 European 
countries was performed. As a result, five key measures were proposed: 
Creating a European RTQA guideline for pediatric CNS tumors, improving the 
collaboration between pediatric oncologists and radiation oncologists, 
building a European central storage system for RT data, implementing 
international RTQA platforms, and promoting European referral networks to 
reduce inequality. 
 
Overall, this thesis shows that there are several aspects to be improved 
in the management of pediatric patients with CNS tumors, and proposes a set 
of pragmatic measures with a three-level approach: local, national and 
international. Hopefully, this work will contribute to the global improvement of 
survival and quality of life of children and adolescents with CNS tumors. 
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El tratamiento de los tumores pediátricos del sistema nervioso central 
(SNC) continúa siendo uno de los mayores retos de la oncología pediátrica 
contemporánea. El objetivo global de este estudio es mejorar el manejo de 
estos pacientes a varios niveles: institucional/local, nacional e 
internacional/europeo. Para ello se han desarrollado tres proyectos: 
En el Proyecto de Investigación #1 se realizó una revisión monocéntrica 
de todos los pacientes pediátricos con meduloblastoma tratados entre 2003 y 
2016 en el Hospital Niño Jesús, Madrid. Aunque la supervivencia global de los 
58 pacientes incluidos fue similar a la observada en estudios poblacionales 
europeos (SG a 5 años: 59%), se propusieron varias medidas para mejorar los 
puntos débiles. Estas medidas incluyen implementar un sistema de calidad, 
promover la inclusión en ensayos clínicos internacionales, establecer una 
revisión central de la anatomía patológica, acelerar la translación del nuevo 
conocimiento molecular a la práctica clínica, e implementar un programa de 
evaluación neurocognitivo y de la calidad de vida. Además, se desarrolló un 
conjunto de 27 indicadores de calidad para evaluar el manejo de estos 
pacientes. 
En el Proyecto de Investigación #2, se revisaron todos los pacientes 
pediátricos con tumores embrionarios del SNC no-meduloblastoma tratados 
en ocho grandes centros oncológicos en España entre 2005 y 2014. Los 43 
pacientes incluidos presentaron un pronóstico desfavorable (SG a 3 años: 
35%), especialmente al compararlos con pacientes incluidos en ensayos 
clínicos. Se propusieron las siguientes medidas asequibles para mejorar el 
desenlace de estos pacientes: establecer una estrategia nacional común, 
implementar circuitos de derivación y redes de colaboración, e incorporar los 
nuevos conocimientos biológicos a la práctica clínica. Además, se inició un 
análisis retrospectivo molecular (perfil de metilación) de las muestras 
tumorales de esta cohorte de pacientes. 
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En el Proyecto de Investigación #3, se analizaron los sistemas de control 
de calidad de la radioterapia a través de los protocolos de ensayos clínicos 
actuales y pasados sobre tumores pediátricos del SNC. Se observó que se 
están desarrollando en Europa diversas iniciativas para implementar un 
sistema de control de calidad de la radioterapia tanto a nivel nacional como 
internacional. Además, se llevó a cabo una encuesta sobre las prácticas de 
control de calidad de la radioterapia en tumores pediátricos del SNC en 21 
países europeos. Como resultado de esta encuesta, se propusieron cinco 
medidas clave: crear una guía europea para tumores pediátricos del SNC, 
mejorar la colaboración entre oncólogos pediátricos y radio-oncólogos, 
construir un sistema central europeo de almacenaje de datos sobre 
radioterapia, implementar plataformas internacionales de control de calidad 
de la radioterapia, y promover redes de colaboración y derivación europeas 
para disminuir la desigualdad entre países. 
 
Globalmente, esta tesis evidencia que hay varios aspectos a mejorar en 
el manejo de los pacientes pediátricos con tumores del SNC, y en ella se 
propone un conjunto de medidas pragmáticas a tres niveles: local, nacional e 
internacional. Esperamos que este trabajo contribuya a la mejoría global en la 
supervivencia y calidad de vida de los niños y adolescentes con tumores del 
SNC. 
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I. INTRODUCTION 
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1. Primary malignant CNS tumors in childhood 
Primary malignant central nervous system (CNS) tumors are the second 
most common childhood malignancies, after hematologic malignancies [1–3]. 
Their estimated incidence varies among different US and European studies 
(2.6-5.4 cases per 100,000 person-years for children and adolescents) [4–6]. 
Primary CNS tumors are a heterogeneous group of neoplasia derived 
from different brain or spinal cord progenitor cells. Their classification has 
been based largely on histological features for the past century, with a complex 
and steadily changing scheme [7]. This relies above all on their diverse and 
insufficiently known underlying biology. However, efforts are being made to 
improve the characterization of each tumor entity. In fact, the latest version of 
the World Health Organization (WHO) classification includes not only 
histology, but also genetic and molecular features as key tools for an accurate 
diagnosis [8]. According to this classification, the two most common CNS 
tumor groups in children are astrocytic and embryonal tumors. 
Although advances in surgical intervention, radiotherapy and 
chemotherapy have improved the survival rates in children with CNS tumors 
over the last 40 years, unacceptable mortality and morbidity rates associated 
with these disorders persist. They constitute the leading cause of death from 
cancer in children, with a 10-year overall survival (OS) for children <15 years of 
65.7-76.1% [9]. Furthermore, survivors face significant sequelae, mainly 
deriving from the complications of surgery and craniospinal radiotherapy.  
Hence, the treatment of pediatric brain tumors remains one of the major 
challenges in modern Pediatric Oncology. The general aim of this study is to 
improve the management of these patients, on a multilevel approach: At an 
institutional/local, national and international/European level. 
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2. CNS embryonal tumors 
 Embryonal tumors (ET) account for 25% of all CNS tumors in patients 
under 18 years. This percentage rises up to 40% when only malignant CNS 
tumors are included. Their treatment is associated with some mortality and 
high morbidity with significant sequelae secondary to surgery, chemotherapy 
and, above all, radiotherapy. 
 CNS-ET affect most frequently young children, with over 20% of them in 
patients <3 years, which hinders their diagnosis and management. 
 As detailed in the WHO classification, CNS-ET have a heterogeneous 
biology. They are highly aggressive tumors (grade IV histology), with a marked 
tendency to spread among the CNS axis. 
 This tumor group includes medulloblastoma, CNS primitive 
neuroectodermal tumors (PNET), and atypical teratoid rhabdoid tumors 
(ATRT), among other rare subtypes. Although these tumors have been formerly 
classified as “primitive neuroectodermal tumors”, this larger group has been 
repeatedly splitting up over the last decades into smaller, more accurately 
defined groups. The growing cytogenetic and molecular knowledge has led to 
differentiate them as distinct histologic entities. 
 In this steadily changing scenario, the term “PNET” has suffered the 
most. When medulloblastoma was separated to an own category, the term 
“supratentorial PNET” was used to define all embryonal tumors that were not 
medulloblastoma. This mixed group was once again redefined in the 2007 
WHO classification to “CNS-PNET”, distinguishing between different subtypes 
as “CNS neuroblastoma”, “CNS ganglioneuroblastoma”, “Medulloepithelioma”, 
and “Ependymoblastoma” (Table 1). In the latest 2016 upgrade, the term 
“PNET” is abandoned, and new, specific entities emerge, such as “embryonal 
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tumor with multilayered rosettes”, ETMR (former “embryonal tumor with 
abundant neuropil and true rosettes”, ETANTR) (Table 2). 
Pineoblastoma, although recently reclassified by the WHO to the group 
of “Tumors of the pineal region”, has been historically included in the group of 
“Embryonal tumors” due to its aggressive histologic and clinical features. 
 
Embryonal tumors (2007) 
Medulloblastoma 
      Desmoplastic/nodular medulloblastoma 
      Medulloblastoma with extensive nodularity 
      Anaplastic medulloblastoma 
      Large cell medulloblastoma 
CNS primitive neuroectodermal tumor 
      CNS Neuroblastoma 
      CNS Ganglioneuroblastoma 
      Medulloepithelioma 
      Ependymoblastoma 
Atypical teratoid / rhabdoid tumor 
 
TABLE 1 The 2007 WHO classification of embryonal tumors. Adapted from [7]. 
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Embryonal tumors (2016) 
Medulloblastomas, genetically defined 
      Medulloblastoma, WNT-activated 
      Medulloblastoma, SHH-activated and TP53-mutant 
      Medulloblastoma, SHH-activated and TP53-wildtype 
      Medulloblastoma, non-WNT/non-SHH 
              Medulloblastoma, group 3 
              Medulloblastoma, group 4 
Medulloblastomas, histologically defined 
      Medulloblastoma, classic       
      Medulloblastoma, desmoplastic/nodular 
      Medulloblastoma with extensive nodularity 
      Medulloblastoma, large cell / anaplastic 
Medulloblastoma, NOS 
Embryonal tumor with multilayered rosettes, C19MC-altered 
Embryonal tumor with multilayered rosettes, NOS  
Medulloepithelioma 
CNS neuroblastoma 
CNS ganglioneuroblastoma 
CNS embryonal tumor, NOS 
Atypical teratoid/rhabdoid tumor 
CNS embryonal tumor with rhabdoid features 
 
TABLE 2 The 2016 WHO classification of embryonal tumors. Adapted from [8]. 
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2.1. Medulloblastoma 
Medulloblastoma is the most common malignant CNS tumor of 
childhood, accounting for 20% of all primary CNS tumors among children. Its 
primary site occurs exclusively in the cerebellum (posterior fossa). However, 
today is clear that medulloblastoma constitutes a unique entity with distinct 
clinical and biological features, far beyond its location. 
Patients with medulloblastoma present symptoms derived from 
increased intracranial pressure and cerebellar dysfunction. They are often 
unspecific and evolve over weeks or months, which can lead to delayed 
diagnosis, particularly in young children. 
Magnetic resonance imaging (MRI) typically shows a contrast-enhancing 
midline or paramedian cerebellar mass [10], but diagnosis requires 
histopathologic confirmation. Approximately one third of patients have 
disseminated disease at diagnosis. Staging should include spinal MRI and 
cerebrospinal fluid cytology obtained preoperatively or two weeks after 
surgery (to avoid contamination with surgical debris) [11–13]. 
Age, extent of disease, extent of resection, histopathologic subtype and, 
recently, molecular subtype are used to stratify patients with medulloblastoma 
into risk groups.  
Children younger than 3-5 years have a significantly poorer prognosis, 
with negative impact on both survival and quality of life. This is partly explained 
by the need to avoid craniospinal radiotherapy in very young children due to 
its toxicity to the developing CNS. 
The modified Chang criteria are used to evaluate the extent of disease 
[14, 15], which also has a negative impact on prognosis (progressively worse 
in the presence of more advanced disease) [16–18]. (Table 3) 
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Type of metastasis 
M0 No evidence of gross subarachnoid or haematogenous metastasis 
M1 Microscopic tumor cells found in the cerebrospinal fluid 
M2 Gross nodular seeding demonstrated in the cerebellar/cerebral 
subarachnoid space or in the third or lateral ventricles 
M3 Gross nodular seeding in the spinal subarachnoid space 
M4 Metastasis outside the cerebrospinal axis 
 
TABLE 3 Modified Chang criteria for the staging of medulloblastoma. 
Adapted from [14]. 
  
Extent of resection is also a major prognostic factor, with gross total or 
near-total resection (residual tumor <1.5 cm2) having a demonstrated positive 
impact on outcome [19]. 
There are several histopathologic subtypes according to WHO 
classification (Tables 1 and 2). They constitute important prognostic factors, 
particularly in young children. Patients with desmoplastic/nodular or 
desmoplastic with extensive nodularity have significantly better prognosis 
compared with the classic form of medulloblastoma. In contrast, those with 
anaplastic/large cell variants show poorer outcome [18]. 
The knowledge gained on biological features of medulloblastoma over 
the last few years has led to the characterization of four molecular subgroups, 
which have distinct histology, genetics, clinical behavior and patient outcomes: 
sonic hedgehog (SHH), Wingless (WNT), group 3 and group 4 [20–22]. Tumors 
with activation of the WNT pathway have the best prognosis, in opposition to 
tumors classified as group 3, which have the worst prognosis [23]. Tumors with 
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activation of the SHH pathway and those in group 4 have an intermediate 
prognosis. SHH tumors with TP53 mutations constitute an important exception, 
with a particularly poor outcome [24]. It is important to note that this biological 
knowledge keeps evolving rapidly; e.g., some recent studies propose to 
expand the molecular classification to seven subgroups [25], while others 
underscore the idea that the currently defined subgroups are likely to be an 
oversimplification of true molecular substructure [26]. 
 
Taking into account the above exposed prognostic criteria (age, extent 
of disease, extent of resection, histopathologic and molecular subtypes), two 
major risk groups emerge, consistent among different international 
workgroups: low/standard (or “average”) and high risk.  
The combination of surgery, craniospinal irradiation (CSI) and 
chemotherapy is the standard of care for children with medulloblastoma. 
Following maximum safe resection, the treatment strategy varies according to 
age and extent of disease. 
The standard risk group includes children older than 3-5 years who have 
undergone a gross total or near-total resection (tumor residue <1.5 cm2) and 
have no evidence of metastases (M0 following modified Chang criteria). After 
surgery, these children receive CSI and adjuvant chemotherapy. For instance, 
one of the most accepted treatment schemes was used in the Children’s 
Oncology Group (COG) medulloblastoma trial A9961 [27]. After tumor 
resection, patients are treated with 23.4 Gy to the craniospinal axis with a 
posterior fossa boost to a total dose of 55.8 Gy, with weekly concurrent 
vincristine. This is followed by eight cycles of chemotherapy (cisplatin, 
vincristine, cyclophosphamide, CCNU). The 10-year event-free and overall 
survival (EFS and OS) rates in this study are 76% and 81% respectively.  
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The high-risk group includes children with metastatic disease, residual 
tumor (≥1.5cm2), or those with adverse histological or biological features (large 
cell/anaplastic subtype, extensive nodularity, MYC or MYCN amplification). 
Their optimal treatment is still unknown, but most trials include CSI given at 
higher doses with concurrent chemotherapy followed by combination 
chemotherapy. There are multiple approaches, for example HART-Milan [28] 
and the more recent COG-ACNS0332 (NCT00392327). In the HART-Milan 
strategy, patients received postoperative chemotherapy in a two-month 
schedule (methotrexate, etoposide, cyclophosphamide, carboplatin), then 
hyperfractionated accelerated radiotherapy (HART) with 39 Gy to the neuraxis 
and a posterior fossa boost of 60 Gy. Patients with persistent disseminated 
disease before HART were consolidated with two myeloablative courses and 
autologous hematopoietic stem cell transplant (aHSCT) (tandem aHSCT). The 
5-year EFS and OS in the original trial were 70% and 73% respectively [28]; 
however, these positive results have not been reproduced in real-life settings, 
and concerns about toxicity have reduced its use [29]. In the COG-ACNS0332 
trial (NCT00392327), patients receive standard therapy consisting of surgery, 
radiotherapy (36 Gy to the neuraxis and 55.8 Gy to the posterior fossa) and 
maintenance chemotherapy (cisplatin, vincristine, cyclophosphamide). 
Subsets of patients are randomly assigned to receive carboplatin 
radiosensitization, isotretinoin during maintenance, both, or neither. 
Infants and young children (< 3-5 years) with medulloblastoma are at risk 
of severe neurologic impairment if their initial treatment includes CSI. A cut-off 
age of 3 years is widely accepted; it was introduced in the 1980s to reduce 
unacceptable sequelae such as severe cognitive decline and impaired spinal 
growth [30–33]. Hence, the protocols designed for these patients use 
combination chemotherapy to either delay or avoid radiotherapy. They often 
include high-dose chemotherapy. For instance, the Head Start I and II 
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strategies in non-metastatic medulloblastoma obtained a 5-year EFS and OS 
of 52% and 70% [34]. However, the long-term effectiveness of substituting 
chemotherapy for CSI remains uncertain. In addition, the increased risk of 
second malignancies is a concern [35].  
In the recently implemented clinical trials such as SIOP-PNET5 
(NCT02066220), histopathologic and molecular features of the tumor are 
being included in the treatment decision algorithms. For instance, extended 
nodularity in young children is considered a good prognostic factor creating a 
new category of “low-risk” patients, which will receive treatment reduction. 
Despite undergoing optimal first line treatment, 20-30% of children with 
medulloblastoma will experience relapse, either locally or among the neuraxis 
[36, 37]. The likelihood of long-term survival after relapse is close to zero. 
Salvage radiotherapy in young children or aHSCT in older children are widely 
used approaches that may achieve a prolonged disease-free survival [38–42]. 
New therapies are emerging, aiming inhibition of molecular targets 
involved in the pathogenesis of medulloblastoma, especially for the SHH 
pathway tumors [43]. In this regard, vismodegib is a promising targeted 
therapy for SHH-driven cases [44–46]. 
For infants younger than three years, only 40-50% of patients survive, 
partly due to the reduction or withdrawal of radiotherapy. Young children with 
disseminated disease at diagnosis have a particularly poor prognosis, with a 5-
year OS of 15-30% [47, 48]. Other prognostic factors have already been 
explained (residual disease after surgery, histological and molecular features).  
Each modality of treatment can cause delayed complications that have 
a profound effect on quality of life in survivors. The most common long-term 
sequelae include posterior fossa syndrome, neurocognitive impairment, 
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hearing loss, endocrine abnormalities, cerebrovascular disease, and second 
malignancies [35, 49–58]. Therefore, upcoming trials are aimed not only to 
improve survival, but also to increase the quality of life of survivors, as well as 
reducing long-term toxicities caused by chemotherapy and radiotherapy. 
 
In Research Project #1, we aim to analyze the management of children 
with medulloblastoma in a major Spanish oncology institution, in order to 
identify weak points that ought to be improved in day-to-day practice. 
 
2.2. Non-medulloblastoma CNS embryonal tumors (former PNET)  
Non-medulloblastoma CNS embryonal tumors (formerly CNS-PNET) are 
poorly differentiated, highly aggressive, neuroepithelial tumors that originate 
from the germinal matrix of the primitive neural tube. They can differentiate to 
diverse cell lineages, so that, for example, tumors with pure neuronal 
differentiation are classified as CNS-neuroblastomas, whereas those with 
mixed neuronal and ganglion cell differentiation are classified as CNS-
ganglioneuroblastomas. Some PNET can be classified according to specialized 
tissue of origin, e.g. pineoblastoma, but most of the remainder originate in the 
cerebral hemispheres and were therefore previously referred to as 
supratentorial PNET [7, 8]. 
Despite the multiple changes that this group of tumors has already 
experienced in their classification and nomenclature (see section “2. CNS 
embryonal tumors”), it is foreseeable that the complexity will grow in the near 
future. Recent epigenetic studies have started a new molecular era in which 
new entities emerge [59–62]. These new entities include “CNS neuroblastoma 
with FOXR2 activation (CNS NB-FOXR2)”, “CNS Ewing sarcoma family tumor 
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with CIC alteration (CNS EFT-CIC)”, “CNS high-grade neuroepithelial tumor 
with MN1 alteration (CNS HGNET-MN1)”, and “CNS high-grade neuroepithelial 
tumor with BCOR alteration (CNS HGNET-BCOR)”. 
CNS-PNET account for less than 5% of CNS embryonal tumors, most of 
them occurring in children younger than 10 years [3, 4]. Symptoms at diagnosis 
are often unspecific. Older children present signs of increased intracranial 
pressure (e.g., headache, vomiting), whereas infants show lethargy, irritability, 
anorexia and enlarged head circumference. Other symptoms may include 
focal deficits or seizures depending on the tumor location. Leptomeningeal 
dissemination can be manifested by cranial nerve palsies, spinal cord 
symptoms or encephalopathy [63]. MRI usually reveals a well-defined, 
hemispheric mass with heterogeneous enhancement. Calcification, necrotic 
areas and intratumoral hemorrhage may be present [64]. 
Traditionally, CNS-PNET have been treated as high risk 
medulloblastomas. The frontline strategy of non-medulloblastoma CNS 
embryonal tumors includes aggressive surgical resection followed by CSI [65, 
66]. In the German 88/89 and 91 HIT trials, a total CSI of 35.2 Gy and a boost 
of 20 Gy to the primary tumor site was reported, achieving a 3-year PFS of 49% 
in children who completed the planned treatment course, in opposition to 7% 
in those with major radiotherapy deviations. Delayed start of radiotherapy (as 
per use of pre-irradiation chemotherapy) resulted in poorer outcome [67]. 
Adjuvant chemotherapy may further improve survival, but the optimal 
chemotherapy strategy is still unknown. Additionally, most regimens have not 
been specifically designed for PNET, but are similar or the same as those 
designed for medulloblastoma. They have been historically evaluated in trials 
with mixed patient populations, e.g. in the HIT 2000 trial [68, 69]. 
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Infants and young children (<3-5 years) are at high risk for severe 
neurologic sequelae if their initial treatment includes CSI, which makes their 
management particularly challenging. Prolonged induction chemotherapy 
regimens have obtained disappointing results, with 5-year OS rates of 15-30% 
[48, 70–72]. High-dose chemotherapy strategies have shown more promising 
results, with one study reporting 5-year OS of 49% [73]. 
Rapid recurrence is common, despite aggressive combined treatment 
[36].  
The reported 3-year OS varies from 48-73% with strategies that include 
radiotherapy. Infants and young children (<3 years) and patients with 
pineoblastoma display a worse prognosis [4, 74–77]. 
In the face of the recently gained knowledge on the biological features 
of CNS-PNET, efforts should be made to correlate these molecular 
classifications to clinical outcomes to implement novel and effective therapies 
[62, 78, 79].  
 
In Research Project #2, we aim to evaluate the current management of 
children and adolescents with CNS-PNET/pineoblastoma in Spain and put it in 
the context of international clinical practice, in order to identify areas of 
improvement at a national level. In addition, we aim to participate in a wider 
international collaboration study that will perform a biological profile 
(methylation array), to analyze the available tumor samples of this patient 
cohort in light of the new epigenetic knowledge.   
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3. Clinical trials versus real-world data 
Despite the general effort to elaborate and implement international 
protocols for the management of pediatric CNS embryonal tumors, the 
obtained results are, albeit universally unsatisfying, not homogenous. The most 
important accomplishments that have been achieved over the past decades 
are a direct consequence of some outstanding clinical trials among the 
diversity of studies that have been performed (e.g. [28, 70, 77, 80, 81]). 
However, when pioneer protocols obtained from clinical trials in 
particular institutions are brought to general clinical practice, the results are 
recurrently disappointing and never as good as they were originally (e.g. [9, 
29, 82]).  
Mounting evidence suggests, on the one hand that results pulled 
outside the context of the clinical trials in which they were acquired are far more 
unprofitable, and on the other hand that facility standards are crucial to ensure 
results’ optimization. Several differential aspects should be considered when 
comparing the clinical trial versus the real-world setting, namely the strict 
patient selection of trials versus the unselected real-world population; the 
more exhaustive and systematized monitoring and follow-up of patients 
throughout treatment and after end-of-treatment in clinical trials; the wide 
implementation of centralized reviews in clinical trials (e.g. central pathology, 
molecular, or imaging review); and the multi-centric organization of most trials.   
In this thesis, we present two real-world data cohorts, one monocentric 
for medulloblastoma (Research Project #1), and one multi-centric and national 
for CNS-PNET (Research Project #2), to identify weak points and propose 
action points to close the gap between real-life and clinical trial patients.  
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To better understand both projects, it is important to underscore that, 
while academic clinical trials are the standard of care in pediatric oncology, 
those trials are not uniformly available. In Spain, no international phase 3 
medulloblastoma trials were open over the last decade until very recently; 
however, SIOP-PNET 5 (NCT02066220) is open in 20 Spanish institutions (the 
first one opening in 2016). For PNET, no trials have ever been available in this 
country. This means that almost all patients included in Research Project #1 
and all patients of Research Project #2 were treated as “per protocol”, as the 
respective trials were not available at that time, and hence both projects 
constitute examples of real-world cohorts. 
In Research Project #3, the topic of clinical trials versus real-world 
settings is also discussed. We present an overview of the current situation of 
radiotherapy quality assurance (RTQA) of pediatric patients with brain tumors 
in Europe, and our perspective on the challenges and on how to move towards 
the future, highlighting the importance of addressing the needs of patients 
treated outside of clinical trials. 
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4. Clinical audit and quality assurance 
The first step towards improvement in the management of complex 
diseases such as pediatric embryonal brain tumors is to identify the existing 
weak points. To do so, reviewing past and current clinical practices at different 
levels (institutional, national and international) is key. Clinical audits and quality 
assurance programs constitute an essential part of good clinical practice [83, 
84]. There is an increasing international interest in the assessment of the quality 
of childhood cancer care using quality indicators (QIs) [85]. In fact, some 
important steps have already been taken regarding the definition of the 
minimal standards of care for pediatric cancer patients. The best example is 
the SIOPe (European Society of Pediatric Oncology) guideline, a  consensus 
document describing the minimum quality requirements for a pediatric 
oncology facility and providing a general directive [83]. 
In spite of this, and of the existence of several sets of QIs for adult cancer 
(e.g. for testicular cancer [86]), there is a lack of specific quality standards 
guidelines and QI systems for childhood cancer. A notable exception to this 
void is provided by a study of the Pediatric Oncology Group of Ontario 
(POGO), in which the authors developed a set of QIs for pediatric cancer care 
[87]. However fruitful the effort is, their proposal is specifically designed for the 
province of Ontario, Canada, and hence hard to extrapolate to other health 
care systems such as the different European countries.  
Moreover, the management of embryonal CNS tumors is particularly 
complex due to their aggressiveness and affected organ, the subsequent high 
severity of illness, the need for multidisciplinary and highly intricate treatments, 
and the potentially severe immediate and long-term toxicities derived from 
them. Thus, there is a need for specific QIs for the management of pediatric 
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brain tumors, against which the overall performance of institutions and 
networks can be compared. 
 
In this challenging era for public healthcare systems, in which high-
quality care is to be provided with limited healthcare resources, we conduct a 
pragmatic study divided in the three mentioned research projects, in search of 
areas of improvement in the management of pediatric patients with CNS 
tumors. We target at three levels: institutional/local, national and European. 
We hope that our findings will serve as a reference to further develop a quality 
assurance system with specific QIs for pediatric CNS tumors in the future, and 
that this will ultimately improve the survival and quality of life of these patients. 
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5. Context of the research projects 
Research Project #1 “Improving the quality of care in the molecular era 
for children and adolescents with medulloblastoma” is a monocentric, 
retrospective study performed at Hospital Infantil Universitario Niño Jesús 
(HNJ), Madrid. This hospital is a reference center for pediatric oncology in 
Spain, with 100-110 new patients per year (4-6 with medulloblastoma). 
Oncological multidisciplinary care is provided for pediatric patients from the 
local region of Madrid and from other parts of Spain. 
 
Research Project #2 “Management and outcome of children and 
adolescents with non-medulloblastoma CNS embryonal tumors in Spain: 
Room for improvement in standards of care” is a multi-centric, retrospective 
study reviewing data from eight major Spanish pediatric oncology hospitals, 
all of them with one member participating in the CNS Tumors Group of the 
Spanish Society of Pediatric Hematology and Oncology (SEHOP).  
In Spain, there are 46 pediatric oncology units treating children and 
adolescents with cancer, according to the national childhood cancer registry 
RETI-SEHOP [88]. However, only 12 centers recruit more than 30 new patients 
per year [88, 89]. Furthermore, there are approximately five to six new cases of 
CNS-PNET per year in Spain. Our research project, spanning 10 years, provides 
data for more than 75% of all cases over that period, as it includes eight major 
Spanish institutions. 
Another aspect to be considered is the persisting inequality across 
Europe, as pointed out by the Eurocare-5 study [90]. From this international 
point of view, Spain is unfortunately not among the countries with the highest 
survival rates, particularly in tumors that require complex multimodal 
treatments, such as CNS embryonal tumors. Hopefully, our research projects 
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will contribute to the efforts to improve survival and quality of life of pediatric 
patients in Spain. 
 
Research Project #3 “Past, present and future of radiotherapy quality 
assurance in pediatric CNS tumors: A European perspective” aims to have an 
overall bird view of the situation of RTQA across Europe. Experts from 21 
countries provide data for this project, which reflects the heterogeneity and 
complexity of the European landscape. To better understand the context of 
this project, the mentioned inequality of outcomes for pediatric cancer patients 
across Europe should be considered [90, 91], as well as the imbalance in 
radiotherapy, with a wide range of levels of access to best-care facilities and 
specialists across European countries [92].  
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II. HYPOTHESES AND 
OBJECTIVES 
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1. AIMS 
The broad aim of this study is to analyze the current multimodal management 
of pediatric patients with central nervous system (CNS) tumors and identify 
opportunities to improve the quality of care at three levels:  
- At a local, mono-centric level, with focus on patients with 
medulloblastoma (Research Project #1) 
- At a national level, with focus on patients with non-medulloblastoma 
CNS embryonal tumors (formerly called “PNET”, primitive 
neuroectodermal tumors) (Research Project #2) 
- At an international, European level, with focus on radiotherapy 
quality assurance (RTQA) as an essential part of the management of 
brain tumors (Research Project #3) 
The final aim of this work is to identify weak points and propose concrete, 
pragmatic measures to improve the outcome of children with CNS tumors.  
 
2. HYPOTHESES 
-  Locally, nationally and internationally, there is a significant gap between 
clinical trial results and actual patient care and real-world data that can 
be better understood and reduced within the frame of quality 
assurance.  
- A thorough evaluation and audit of treatment practices and survival 
outcomes of pediatric patients with embryonal CNS tumors 
(medulloblastoma and PNET) treated in Spanish hospitals will allow 
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identifying weak points and improvement opportunities in the 
management of these patients (Research Projects #1 and #2). 
- The development and future implementation of a set of pragmatic 
measures to tackle the identified weak points in the multimodal 
treatment of pediatric embryonal tumors in Spain will lead to improved 
outcomes (Research Projects #1 and #2). 
- The review of current and past RTQA practices for pediatric CNS tumors 
across Europe will help the ongoing construction of international RTQA 
programs that will further optimize the irradiation treatment, maximizing 
survival rates and reducing long-term sequelae (Research Project #3). 
- The follow-on projects derived from this thesis, including molecular 
classification with tissue microarrays of the local medulloblastoma 
cohort; molecular diagnostic re-evaluation with methylation profiling of 
the Spanish CNS-PNET cohort as part of a world-wide collaboration 
study and an international survey on the RTQA practices across Europe 
in collaboration with EORTC will increase institutions’ collaboration at a 
national and international level, and help build strong research 
networks, which will benefit patients in the mid-term and improve their 
outcomes. 
 
These hypotheses translate into the following objectives: 
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3. OBJECTIVES 
Research Project #1: 
I) To conduct an analysis of treatment strategies and outcomes (toxicity 
and survival) in a real-world cohort of pediatric patients with 
medulloblastoma in a Spanish reference pediatric oncology center  
II) To identify weak points and to propose a set of quality indicators to 
implement at a local/institutional level 
 
Research Project #2: 
III) To conduct an analysis of treatment strategies and outcomes (toxicity 
and survival) in a real-world cohort of pediatric patients with CNS-
PNET in Spain (multi-centric review) 
IV) To identify weak points and improvement opportunities  in CNS-
PNET to implement at a local and national level.  
V) To set the foundations of a collaboration at the ongoing world-wide 
study for molecular diagnostic re-evaluation with methylation 
profiling of CNS-PNET (led by the German Cancer Research Center, 
DKFZ) that will lead to the implementation of the methylation profiles 
in routine clinical practice 
 
Research Project #3: 
VI) To review and analyze past and current practices in RTQA for 
pediatric patients with brain tumors across Europe (description of 
national and international RTQA programs and initiatives) 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
56 
VII) To perform an international survey in an “ask-the-expert” approach 
to gather information about the current practices of RTQA across 
Europe, approaching both pediatric neuro-oncologists and radio-
oncologists. 
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III. RESEARCH PROJECT #1: 
 
 
 
 
Improving the quality of care in the molecular 
era for children and adolescents with 
medulloblastoma  
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1. INTRODUCTION  
  
Medulloblastoma is the most common malignant central nervous system 
(CNS) tumor of childhood, accounting for 20% of all primary CNS tumors 
among children [6, 93]. It is an aggressive, embryonal tumor that requires 
multimodal treatment to achieve the current survival rates (global 5-year OS of 
56%; 67% for children >4 years) [93, 94]. Gross-total resection (GTR) and 
receiving radiotherapy as frontline treatment continue to be two of the most 
important prognostic factors. This gives an idea of the importance of treating 
children with medulloblastoma in highly specialized centers, and of 
implementing quality assurance programs to ensure best management of such 
complex patients. 
 Another cornerstone is the gained knowledge on biological features of 
medulloblastoma over the last few years, which has led to the characterization 
of four molecular subgroups, with distinct histology, genetics, clinical behavior 
and patient outcomes: sonic hedgehog (SHH), Wingless (WNT), group 3 and 
group 4 [20–22]. This new knowledge has been incorporated into the most 
recent 2016 WHO CNS tumor classification [8]. Furthermore, in the current 
clinical trials, histopathologic and molecular features are being included in the 
treatment decision algorithms. For instance, in the recently started SIOP-PNET 
5 (NCT02066220), patients <16 years within the WNT subgroup are 
considered to have a better prognostic, and hence are assigned to a new “low 
risk” category, which will receive treatment reduction.  
This new molecular era will allow to better tailor the treatment for each 
patient, optimizing survival and reducing long-term toxicities. Beyond that, 
new therapies are emerging, aiming inhibition of molecular targets involved in 
the pathogenesis of medulloblastoma, especially for the SHH pathway tumors 
[44, 46].  
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 However, there seems to be a significant delay in the incorporation of 
molecular advances into daily practice, leaving specially patients treated 
outside clinical trials behind.  
 We present a study conducted at Hospital Niño Jesús (HNJ), Madrid, a 
reference center for pediatric oncology in Spain, with 100-110 new patients 
per year (4-6 with medulloblastoma). The aim of this study is to present a real-
world cohort of children and adolescents with medulloblastoma, to search for 
weak points in their management that can be improved at a local/institutional 
level, and to analyze the use of molecular markers and their incorporation into 
clinical decision making.  
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2. METHODS 
 
2.1. Patient identification 
 The experience of one major Spanish pediatric cancer hospital (HNJ) is 
collected. The hospital’s clinical database was queried for all patients with the 
diagnosis of “medulloblastoma” between 2003 and 2016.  
 Local institutional approval was granted for the retrospective chart 
review.  
 
2.2. Eligibility 
 Inclusion criteria were histologically confirmed diagnosis of CNS-
medulloblastoma (according to the 2000, 2007, or 2016 WHO classification 
depending on the time of diagnosis [7, 8, 95]), age 0-21 years at diagnosis, 
time of diagnosis between January 2003 and December 2016, and fully 
available clinical data.  
 
2.3. Record review 
 In total, 82 variables were collected (in patients with no 
relapse/progression). Additional 66 variables were collected for each 
relapse/progression. Data collected included: 
- Demographic and baseline information: sex, date of birth, hospital(s) 
where the patient was diagnosed/received frontline treatment/received 
salvage treatment if any, personal and family history.  
- Diagnostic characteristics: age and symptoms at diagnosis, duration of 
main symptom, date of diagnosis, size (magnetic resonance imaging, 
MRI) and location of the primary tumor, extent of disease (M stage, 
diffuse infiltration, nodules), histology, molecular markers (including 
beta-catenin, SHH, p53, C-myc, N-myc, and 6-monosomy).  
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- Frontline treatment:  
o Global treatment strategy 
o Surgery: date and extent of surgical resection, size of tumor rest, 
management of intracranial hypertension, surgery of metastasis, 
surgical complications/toxicities, second surgery (type, 
motivation and outcome).  
o Radiotherapy: start and end dates, modalities, type of fractioning, 
site, dose (total, posterior fossa, boost, craniospinal irradiation –
CSI-), administered percentage of dose, acute toxicity. 
o Chemotherapy: regimen, start and end date, protocol 
modifications (time-intensity modifications, dose-intensity 
modifications, agent withdrawal), intrathecal chemotherapy, 
toxicities that lead to protocol modifications.  
o Autologous hematopoietic stem cell transplantation (aHSCT): 
date, disease status and comorbidities pre-aHSCT, conditioning 
regimen, toxicities (first 100 days), disease status post-aHSCT. 
o Novel strategies/drugs (clinical trials, off-label) 
o End of treatment: date and disease status 
- Relapse/Progression: for each relapse/progression, date of diagnosis, 
diagnostic motivation (symptoms vs per imaging per protocol), relapse 
disease characteristics (location, extension), new histopathology, and all 
variables detailed in the previous section (“Frontline treatment”) were 
collected. 
- Outcome: live and disease status, date of last follow-up/date of death, 
cause of death, long-term toxicities/sequelae, rehabilitation treatment, 
palliative care.  
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Pathology records were reviewed in light of the latest 2016 WHO 
classification [8]; this nomenclature is used to present the results. 
Size and location of primary tumor was assessed by the diagnostic MRI.  
Size of the primary tumor was measured in three dimensions. Standard Chang 
M-stage classification was used [15]. 
Extent of resection was determined from the operative report as well as 
post-operative MRI. Gross total resection (GTR) was defined as no evidence of 
enhancing tumor on post-operative imaging. Subtotal resection (STR) was 
defined as any surgical resection less than GTR. A third designation, “biopsy 
only”, was given to patients whose operative note included that text. 
A distinction was made regarding the tumor rest after the first and 
second-look surgery (if performed as part of the frontline treatment), between 
<1.5 cm2 vs ³1.5 cm2, as measured by MRI. Post-surgical MRI scans were 
performed within 48 hours of surgery, as internationally defined.  
For this analysis, in the absence of comprehensive molecular analysis for 
most patients, three risk groups were considered: Younger children (age <3 
years), standard risk (SR) and high risk (HR). Patients older than 3 years and with 
any of the following features were assigned to the HR group: tumor rest ³1.5 
cm2, anaplastic histologic subtype, or M+. Patients older than 3 years and with 
none of these three features were considered to have SR disease. 
Radiotherapy (RT) was given at Hospital Gregorio Marañón, Madrid. 
Chemotherapy (CT) modifications were defined as time-intensity 
deviations (delay >1 week between cycles), dose-intensity deviations (>10% 
dose reduction of CT agents) and/or CT agents withdrawal.  
Toxicities were evaluated following the National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE), v.4.03 [96]. Only 
grade 3-4 toxicities were collected, with the exception of acute RT toxicities (all 
were collected).  
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2.4. Statistical analysis 
To calculate time intervals, the following definitions were followed: 
- The date of diagnosis was considered the date of the diagnostic MRI. 
- Time to diagnosis is equivalent to symptom duration.  
- Time to surgery: from the date of diagnosis to the date of initial surgery.  
- Time to radiotherapy: from the date of surgery to the start date of 
irradiation therapy (in those patients that received radiotherapy 
upfront).  
- Radiotherapy duration: from the start date to the end date of irradiation 
treatment.  
- Time to chemotherapy: from the end date of radiotherapy to the start 
date of chemotherapy (in those patients that received radiotherapy 
upfront without concomitant CT).   
- Chemotherapy duration: from the start date to the end date of 
chemotherapy (last day any CT was administered). 
- Frontline treatment duration: from the date of initial surgery to the date 
of end of treatment (date of last administered therapy, regardless of the 
modality). 
- Time to progression: from the date of diagnosis to the date of radiologic 
progression.  
 
Endpoint of analysis for all patients was either the date of last follow-up 
or date of death.  
Survival was estimated using the Kaplan-Meier method, and the exact 
log-rank test was used for comparisons of survival in different groups. 
Progression free survival (PFS) was calculated as the time from diagnosis to the 
date of first progression or relapse, or the date of last follow-up. Overall survival 
(OS) was defined as the time from first diagnosis to death of any cause or the 
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date of last follow-up. Log-rank test was applied to identify significant 
prognostic factors for PFS and OS. 95% confidence intervals (CI) were 
provided. The significance level was fixed for all P values under 0.05.  
Analysis was performed using the free software R, version 3.4.0. The 
ability to do multivariate analysis was limited due to the small sample size and 
was therefore not performed.  
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3. RESULTS 
 
3.1. Patient demographics and presentation 
Sixty-six patients aged 0-21 years with histological diagnosis of 
medulloblastoma were identified. Eight patients were excluded from this 
analysis due to incomplete medical records (Figure 1). That yielded 58 eligible 
patients (40 male, 18 female).  
 
 
 
FIGURE 1 Flow diagram of patients. HR: High Risk, SR: Standard Risk 
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Demographic and diagnosis characteristics are shown in Table 1. The 
median age at diagnosis was 5.0 years (range 0.6-15.1). One of the patients 
was diagnosed of Gorlin syndrome after the diagnosis of medulloblastoma 
[97]. No other patient had relevant medical history or identified genetic 
disorders.  
At presentation, symptoms were heterogeneous, with headache or 
vomiting occurring in 81% of patients (Table 1), and being the main symptom 
in 71%. Median duration of the main symptom was 4 weeks (range 0.1-60). 
Regarding the diagnostic MRI scan, median longest diameter of primary 
tumor was 42 mm (range 17.0-77.0). At diagnosis, 19/56 patients (34%) 
presented with metastatic disease. Three patients were classified as M1 (5%), 
four as M2 (7%) and 12 as M3 (22%). In two patients, the M status at diagnosis 
was unknown. 
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Patient and tumor characteristics No. % 
Sex                                                              n=58 
  Male 40 69 
  Female 18 31 
Age                                                             n=58 
  <3 years 14 24 
  >3 years 44 76 
Symptoms at diagnosis                          n=58  
  Headache 32 55 
  Vomiting 41 71 
  Ataxia/Gait impairment 24 41 
  Neurocognitive symptoms 10 17 
  Diplopia 8 14 
Histology                                                   n=54 
  Classic 42 78 
  Nodular/Desmoplastic 5 9 
  With extensive nodularity 2 4 
  Large cell/Anaplastic 3 5 
  Not otherwise specified (NOS) 2 4 
M Chang Stage                                        n=56 
  M0 37 66 
  M1 3 5 
  M2 4 7 
  M3 12 22 
  M4 0 N/A 
Type of metastasis (if M2/M3)               n=16 
  Nodules 3 19 
  Sugar coating 7 44 
  Both 5 31 
  Unknown 1 6 
 
TABLE 1 Baseline characteristics 
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3.2. Biological features 
Histologic subtypes according to the WHO 2016 criteria were classic 
(n=42/54, 78%), nodular/desmoplastic (n=5, 9%), with extensive nodularity 
(n=2, 4%), large cell/anaplastic (n=3, 5%) and NOS (not otherwise specified) 
(n=2, 4%). In four patients, the subtype was unknown. 
Twenty-four patients were diagnosed with medulloblastoma after 2011 
when the four molecular subgroups were defined [21]. However, the 
determination of molecular markers was not implemented until January 2013 
in HNJ Pathology Department. Since then, a national central review panel has 
been convened, all diagnostic samples are sent to the national coordinating 
center in Bilbao. From 2013, 19 patients were newly diagnosed, but only eight 
(42%) have an available complete molecular profile including Beta-catenin, 
p53, c-Myc, and N-Myc. All markers were negative in all eight cases. Two of the 
samples were also studied for monosomy 6 (also negative). Additionally, in 
three samples an isolated Beta-catenin test was performed, one of them with 
nuclear positivity. Six samples were tested for activation of the SHH pathway, 
with negative result. The comprehensive four-group classification [21] has not 
been fully implemented at a national level. 
 
3.3. Referral pathway 
The referral path of the patients is reflected in Table 2 and Figure 2. The 
first line of treatment was administered at Hospital Niño Jesús, Madrid, in 45/58 
patients (78%); in four of them, initial surgery was performed in a different 
institution (but the rest of the first line was completed at HNJ). Three patients 
(5%) were referred to HNJ for aHSCT. The remaining ten patients (17%) were 
referred to HNJ after relapse. 
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Treatment Milestones Patients HNJ Other institutions 
Initial diagnostic suspicion  
(CT or MRI)  n=58 20 (34%) 38 (66%) 
First surgery  n=58 41 (71%) 17 (29%) 
Frontline treatment (other than 
surgery)   n=57 * 44 (77%) 13 (23%) ** 
Any salvage treatment (at least 
one line of salvage treatment)  n=31 31 (100%) 2 (6%) *** 
First salvage treatment n=31 30 (97%) 1 (3%) 
Second salvage treatment n=13 13 (100%) 0 
Third salvage treatment n=5 3 (60%) 2 (40%) 
Fourth salvage treatment n=3 3 (100%) 0 
 
HNJ: Hospital Niño Jesús, Madrid. 
 
* One patient died due to brain hemorrhage five days after the initial surgery 
(and thus did not receive any other treatment). 
** Three of these patients underwent aHSCT at HNJ as frontline treatment. 
*** One patient was treated in two different institutions (other than HNJ) for the 
first and third salvage lines. 
 
TABLE 2 Treatment center for the different treatment modalities received 
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FIGURE 2 Referral pathway. The colors reflect where the treatment milestones 
occurred: Yellow, Hospital Niño Jesús (HNJ); blue, other institutions; grey, if not 
applicable (i.e., the patient did not undergo that milestone). Of note: Patients 9, 11 
and 33 were referred to HNJ to undergo aHSCT. Note how most patients are 
diagnosed in other institutions and referred to HNJ for treatment. Note also how most 
salvage treatments are performed at HNJ, and how most patients, once referred to 
HNJ, stay there for the rest of treatment milestones. 
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3.4. First line treatment 
3.4.1. Global strategy 
Frontline treatment strategy changed over time throughout the years of 
the study (2003-2016), but was consistent within patients treated at HNJ 
(Tables 3 and 4). Younger children (<3 years) were treated with radiation-
sparing protocols: SFOP (French Society of Pediatric Oncology) [47] from 2003 
to June 2005; Head Start II [34] from July 2005 to 2016. Older children (>3 
years) and adolescents were treated according to their risk stratification: 
Standard-Risk patients followed SIOP-PNET 4  [98] from 2003 to 2015, and 
SIOP-PNET 5 (NCT02066220) since 2016; High-Risk patients were treated 
following HART-Milan [28] until 2014, and COG-ACNS0332 (NCT00392327) 
since 2015. In other institutions, patients were treated following different 
protocols (e.g. Packer, UKCSSG 2001) (Table 4). Three patients were included 
in the SIOP-PNET 5 trial, which opened at HNJ in 2016. The rest of the patients 
were treated as “per protocol”, as the respective trials were not available at 
HNJ at that time.  
The treatment strategies had a common basis; all of them included 
surgery with the widest possible resection. Additionally, CSI was administered 
whenever the patient’s age allowed it (patients older than 3 years). Hence, 
patients were treated upon two main categories, radiation-sparing and 
radiation-inclusive protocols, depending on their age, with a cut off between 3 
and 4 years; the use of radiotherapy on first line applied for older patients, and 
sparing or delaying radiation for younger patients. Following this classification, 
16 patients (27%) were treated with treatment strategies designed to avoid 
radio-induced brain damage, whereas 41 patients (71%) were treated with 
radiation-inclusive regimens. (One patient died shortly after surgery). 
Chemotherapy (CT) was used as consolidation in patients receiving RT upfront, 
and to delay RT in radiation-sparing protocols. Another extended first-line 
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modality was aHSCT, with 14 patients (24%) undergoing transplant (nine within 
radiation-sparing strategies, five within radiation-inclusive strategies). 
 
Frontline treatment No. % 
Global strategy                                          n=58 
  SIOP-PNET 4 [98] 27 47 
  SIOP-PNET 5 (NCT02066220) 3 5 
  HART-Milan [28] 6 10 
  COG-ACNS0332 (NCT00392327) 2 3.5 
  SFOP [47] 2 3.5 
  Head Start II [34] 11 19 
  Others 7 12 
Treatment modalities                               n=58 
  Surgery 58 100 
      Gross total resection 34 59 
      Subtotal resection 21 36 
      Biopsy only 3 5 
      Second look 4 7 
      GTR after second look 1 2 
  Radiotherapy upfront 41 71 
      >4 years old 34 59 
      3-4 years old 7 12 
      Only local field (focal RT) 0 NA 
      Local field + CSI 41 71 
      Hyperfractionated RT 6 10 
      No RT upfront 17 29 
  Chemotherapy   
      Systemic CT 57 98 
      Intrathecal CT 8 14 
      aHSCT 14 24 
      No CT upfront 1 2 
 
aHSCT: Autologous Hematopoietic Stem Cell Transplantation; CSI: Craniospinal 
irradiation; CT: Chemotherapy; GTR: Gross total resection; NA: Not applicable; RT: 
Radiotherapy. 
 
TABLE 3 Frontline treatment characteristics 
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Treatment Milestones Younger Children n=14 
High Risk 
n=21 
Standard Risk 
n=23 
Global strategy SFOP Head Start II 
HART-Milan 
COG-ACNS0332 
SIOP-PNET 4 
SIOP-PNET 5 
GTR 6 (43%) 8 (38%) 21 (91%) 
Radiotherapy 0 19 (90%) 22 (96%) 
aHSCT  9 (64%) 5 (24%) 0 
Live status Dead 7 (50%) Alive 7 (50%) 
Dead 9 (43%) 
Alive 12 (57%) 
Dead 7 (30%) 
Alive 16 (70%) 
 
aHSCT: Autologous Hematopoietic Stem Cell Transplantation; GTR: Gross total 
resection. 
 
TABLE 4 Frontline treatment characteristics according to risk groups 
 
 
3.4.2. Surgery  
All patients underwent surgery on the first-line approach. Median time 
to surgery (from MRI diagnosis) was four days (range 0-64). Among patients 
who underwent initial surgery at HNJ (n=41), median time from diagnosis to 
surgery was four days (range 2-28) for those diagnosed at HNJ (n=19) versus 
four days (range 1-64) for those diagnosed at other institutions (n=22). For 
patients that underwent initial surgery at other institutions (n=17), median time 
to surgery was two days (range 0-43).  
GTR was accomplished on first surgery in 34/58 patients (59%) and on 
second-look surgery in one patient (2%). In 20 patients (34%) only STR was 
achieved, despite three of them undergoing a second-look surgery.  
Forty-three patients (n=54, 80%; 4 unknown) showed grade 3-4 severe 
surgical complications: cranial nerves paresis/paralysis (n=17/54, 31%), 
mutism/posterior fossa syndrome (n=14, 26%), infection (n=13, 24%). One 
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patient underwent second surgery for ventriculoperitoneal shunt repair. One 
patient died five days after surgery due to massive tumor hemorrhage, while 
three other patients survived brain hemorrhage after surgery (without second 
surgery). 
 
3.4.3. Radiotherapy  
RT was administered to 41 patients (n=58, 71%) as frontline treatment, 
all of them with CSI. Indeed, all children aged 4 and above received CSI as part 
of frontline treatment, excepting the one that died due to surgical 
complications. Between 3 and 4 years of age, most patients received CSI as 
well, with the exception of two patients (3.1 and 3.2 years) who did not receive 
RT on first line, undergoing radiation-sparing treatment protocols instead.  
For 31 patients that received RT right after surgery, median time from 
surgery to RT start was 39 days (range 3-127). The patient receiving RT three 
days after surgery underwent only a biopsy and was in a critical neurological 
condition. 
Median dose to the posterior fossa was 54 Gy (range 54.0-68.0), while 
median CSI dose was 23.4 Gy (range 23.4-39.8). In two patients, 8 Gy were also 
administered as a boost to the tumor bed. 
Median duration of RT was 43 days (range 30-75). Most patients 
(n=14/26, 54%; 15 unknown) presented acute toxicity (first three months after 
RT start date), which consisted mainly of grade 1-2 radiodermatitis (n=7/14, 
50% of patients with toxicity), grade 2-3 gastrointestinal toxicities (dysphagia, 
mucositis, vomiting) (n=6, 43%). Two patients had grade 4 pancytopenia, and 
one had a grade 4 disseminated infection caused by herpes simplex virus 1 
and varicella-zoster virus.  
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3.4.4. Chemotherapy  
All patients but one received CT as part of their first line treatment 
(n=57/58, 98%). The patient not receiving CT was the one deceased after 
surgery. When combined with irradiation (n=41), CT was administered as 
consolidation after RT in 33 (80%) patients, and prior to RT (or as a “sandwich”) 
in eight (20%) patients. 
Intrathecal CT was used in 14% of the patients (n=8/58) as part of 
frontline treatment, mostly in younger children (<4 years), and it was mainly 
based on intrathecal cytarabine (5 patients) and intrathecal liposomal 
cytarabine (3 patients).  
Median duration of systemic CT treatment was 6.2 months (range 1.5-
19.0). For patients receiving conventional Packer chemotherapy (i.e. patients 
treated following SIOP-PNET 4), median duration of CT was 10.0 months 
(range 1.5-13.3). Of note: the median duration is lower than the theoretical 
Packer regimen duration (10.3 months) because almost half of the patients 
(13/27, 48%) did not complete the eight foreseen cycles (due to toxicities 
and/or disease progression). Up to 63% of patients (n=34/54, 4 unknown) 
required significant modifications on the original CT plan due to 
chemotherapy-related toxicities. Forty-two percent (n=22/53, 5 unknown) had 
time-intensity modifications, with at least one significant delay on a CT-cycle 
start. Twenty-six percent (n=14/53, 4 unknown) had dose-intensity 
modifications, with at least one CT agent dose reduction (at least 10% over 
initial dose). In 28% (n=15/53) of the patients at least one CT agent had to be 
withdrawn or substituted with another agent (e.g. cisplatin substituted for 
carboplatin due to tubulopathy or ototoxicity).  
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3.4.5. Autologous HSCT  
aHSCT was performed as part of the first-line strategy on 14 patients 
(24%), in five (36%) of them in combination with irradiation. It followed RT as 
consolidation treatment in all five of them. Only one of them underwent a 
double tandem transplantation (n=1/14, 7%). Patients were on situation of 
complete response (n=8, 57%) or partial response (n=6, 43%) prior to starting 
aHSCT. One of the patients went from partial response to complete response 
after aHSCT, one went from partial response to progressive disease, and the 
rest had the same disease status after aHSCT. Eight patients (57%) had grade 
3-4 post-HSCT toxicities aside from hematologic toxicities, including mucositis, 
engraftment syndrome, bacteremia, and varicella-zoster infection. One patient 
treated following the HART-Milan protocol developed tetraparesis and need 
for mechanical ventilation after receiving thiotepa as conditioning regimen 
after radiotherapy. 
 
3.5. Toxic mortality and second malignancies 
One patient (2%) died due to toxicity, five days after surgery (massive 
tumor bleeding). No patients died due to CT or acute RT toxicity. During follow-
up, four patients (7%) developed second malignancies: Two patients 
developed myelodysplastic syndrome, one of them dying 4.4 years after the 
diagnosis of medulloblastoma due to septic shock in the context of the 
myelodysplasia (the same patient that suffered from tetraparesis after the use 
of thiotepa, mentioned above); one patient developed several basal cell 
carcinomas over the irradiation zones, and was diagnosed with Gorlin 
syndrome [97]; and one patient developed a high-grade diffuse astrocytoma, 
3.6 years after completing the RT treatment, and started combination therapy 
with RT and temozolomide. 
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3.6. Relapse and patterns of failure 
Thirty-one (53%) patients experienced relapse. Median time to first 
relapse was 13.8 months (range 2.4-50.2). Twenty (65%) patients had received 
RT as frontline treatment. 
Thirteen patients (n=58, 22%) had a second relapse, five (9%) a third 
relapse, and three (5%) a fourth relapse. 
First relapse was local in 5/31 patients (16%), metastatic in 15 patients 
(48.5%), and both local and metastatic in 11 patients (35.5%). From the 26 
patients with metastatic relapse, eight patients (30.5%) presented with 
nodules, nine patients (35%) had diffuse infiltration (“sugar coating”), and eight 
(30.5%) had both. One patient (4%) had M4 disease, with a bone metastasis. 
 
3.7. Salvage treatment on first relapse 
Surgery was used on 10/31 patients (32%): in two patients for 
ventriculoperitoneal shunt repair/placement; in one patient for biopsy; in one 
patient to achieve GTR of the relapsed primary tumor (unsuccessfully); and in 
six patients to remove metastatic nodules. RT was used on 12/31 patients 
(39%). Five (42%) of them had received RT previously as first line approach and 
had focal re-irradiation. In 29/31 patients (94%) chemotherapy was used, 16 of 
them (55%) with diverse irinotecan-temozolomide regimens [99]. Twelve 
patients (41%) also received intrathecal chemotherapy and another three 
underwent aHSCT. Only two patients (n=31, 6%) were enrolled in early phase 
clinical trials and received novel agents: a first-in-child trial of Celyvir  
(NCT01844661) and a phase II study of irinotecan in combination with 
temozolomide [99]). There are 10 survivors (32%) among the relapsed patients, 
with a median follow-up of 5.8 years (range 2.2-10.9). At initial diagnosis, five 
of them (50%) had been classified as HR, three (30%) as SR, and two of them 
(20%) were younger children (<3 years).   
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3.8. Outcomes and prognostic factors  
Median follow-up for survivors was 5.2 years (range 0.7-13.0). See figure 
3 with a swimmer survival plot representing the study population.  
For the whole population, 3-year and 5-year PFS were 43% (95%CI 32-
59%) and 37% (95%CI 25-53%), respectively. Three-year and 5-year OS were 
68% (95%CI 57-82%) and 59% (95%CI 47-75%), as shown in figure 4.  
 By risk group, 5-year PFS were 28% (95%CI 11-71%) for younger 
children (<3 years), 25% (95%CI 11-57%) for HR patients (>3 years), and 52% 
(95%CI 33-79%) for SR patients (>3 years). Five-year OS were 44% (95%CI 23-
84%), 51% (95%CI 32-81%), and 77% (95%CI 61-97%), respectively (see figure 
5). 
Metastatic disease at diagnosis and not having been irradiated on first 
line were variables significantly associated with worse outcome in the 
univariate analysis (p<0.05), with impact on both PFS and OS (see Figure 6 and 
Table 5). 
 
For comparability, outcomes for patients treated at HNJ from initial 
surgery (n=41) are reported here: 3-year and 5-year PFS were 54% (95%CI 40-
72%) and 44% (95%CI 30-64%), respectively. Three-year and 5-year OS were 
69% (95%CI 56-85%) and 58% (95%CI 44-76%), as reflected in figure 7. Among 
these patients, 5-year PFS by risk group were: 25% (95%CI 8-83%) for younger 
children (<3 years), 30% (95%CI 14-65%) for HR patients (>3 years), and 70% 
(95%CI 49-100%) for SR patients (>3 years). Five-year OS were 25% (95%CI 8-
83%), 50% (95%CI 30-82%), and 87% (95%CI 71-100%), respectively. 
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FIGURE 3 Swimmer survival plot for all series. 
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FIGURE 4 Kaplan-Meier Curves for all series. A, Overall Survival. B, 
Progression Free Survival 
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FIGURE 5 Kaplan-Meier Curves according to risk group.  
A, Overall Survival. B, Progression Free Survival.  
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FIGURE 6 Kaplan-Meier Curves for Overall Survival according to disease 
extension at diagnosis (A) and to radiotherapy as frontline treatment (B). 
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Variable 5-year PFS  (95% CI) Log-Rank 
5-year OS  
(95% CI) Log-Rank 
Gender 
(Female vs Male) 
17% (5-60%) vs 
42% (29-62%) p = 0.383 
45% (23-87%) vs 
64% (50-81%) p = 0.598 
Duration of symptoms 
(£4 weeks vs >4 weeks) 
44% (30-65%) vs 
25% (8-74%) p = 0.354 
62% (47-81%) vs 
59% (36-95%) p = 0.552 
Age at diagnosis 
(<3 years vs ³3 years) 
28% (11-71%) vs 
39% (26 - 58%)  p = 0.168 
44% (23-84%) vs 
64% (50-81%) p = 0.256 
Disease extension 
(M0 vs M1-4) 
47% (33-67%) vs 
91% (1-55%) p = 0.047 
73% (59-89%) vs 
28% (12-67%)  p = 0.008 
Risk Group (SR vs HR 
and young children) 
52% (33-79%) vs 
26% (14-48%)  p = 0.111 
77% (61- 97%) vs 
48% (33-70%) p = 0.249 
Time to surgery  
(£4 days vs >4 days 
36% (22-58%) vs 
39% (21-70%) p = 0.504 
59% (44-79%) vs 
57% (38-85%) p = 0.723 
Extent of resection 
(GTR vs Non-GTR) * 
35% (21-58%) vs 
38% (21-67%)  p = 0.838 
60% (44-81%) vs 
58% (40-83%) p = 0.98 
Surgical rest 
(<1.5 cm vs >1.5 cm) 
37% (23-58%) vs 
35% (17-69%) p = 0.637 
59% (44-79%) vs 
60% (40-89%)  p = 0.869 
Radiotherapy 
(No vs Yes) 
23% (9-60%) vs 
42% (28-62%) p = 0.007 
42% (23-76%) vs 
66% (52-84%)  p = 0.044 
Time to radiotherapy  
(£40 days vs >40 days) 
56% (36-85%) vs 
48% (25-94%) p = 0.94 
73% (54-97%) vs 
70% (47-100%) p = 0.712 
CT time-intensity 
deviations (No vs Yes) 
43% (27-70%) vs 
34% (19-62%) p = 0.312 
62% (45-86%) vs 
52% (35-79%) p = 0.434 
CT dose-intensity 
deviations (No vs Yes) 
38% (25-59%) vs 
37% (17-85%) p = 0.913 
60% (45-79%) vs 
48% (26-89%) p = 0.671 
Treatment center  
(HNJ vs Outside 
HNJ)** 
44% (30-64%) vs 
16% (4-55%) p = 0.096 
58% (44-76%) vs 
65% (44-96%) p = 0.629 
GTR: Gross Total Resection; HNJ: Hospital Niño Jesús; HR: High Risk; OS: Overall 
Survival; PFS: Progression-Free Survival; SR: Standard Risk. 
 
In bold letters, those comparisons that reach statistical significance (p<0.05). 
* GTR achieved after first or second-look surgery 
** Patients that underwent frontline treatment from surgery at HNJ (vs those who 
were referred for only one part of frontline treatment or for salvage therapies) 
 
TABLE 5 Five-year Progression-Free Survival and Overall Survival according to 
different baseline variables 
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FIGURE 7 Kaplan-Meier Curves for patients treated at HNJ from surgery. 
 A, Overall Survival. B, Progression Free Survival 
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3.9. Time-related indicators across different frontline treatment milestones 
The timeline measurements were performed as quality indicators of the 
frontline treatment, as shown in table 6. 
 
Time indicators Global N (HNJ/Outside) Global HNJ Outside HNJ 
Time to diagnosis [weeks] 
(symptoms duration) 51 (39/12) 4 (0.1-60) 4 (0.1-60) 3.5 (0.7-20) 
Time to surgery [days] 57 (41/16) 4 (0-64) 4 (1-64) 1.5 (0-43) 
Time to radiotherapy [days] 31 (23/8) 39 (3-127) 36 (3-127) 40.5 (24-73) 
Radiotherapy duration 
[days] 37 (28/9) 43 (30-75) 42 (30-75) 45 (30-58) 
Time to chemotherapy 
[days] 23 (17/6) 42 (7-53) 42 (7-53) 36 (25-48) 
Chemotherapy duration 
[months] 54 (39/15) 6.2 (1.5-19) 7.5 (1.5-15) 4.1 (1.5-19) 
Frontline treatment 
duration [months] 56 (40/16) 9.4 (2.1-19.7) 10.6 (2.1-17.4) 9.0 (3.7-19.7) 
HNJ: Hospital Niño Jesús 
 
Patients are divided in two groups: those that underwent frontline treatment from 
surgery at HNJ versus those that were referred to HNJ for only one part of the frontline 
treatment or for salvage therapies. 
Median and range values (in parentheses) are shown. 
The number of patients for which the measurement was done is reflected in the “N” 
column (taking into account missing values and applicability of each measure). 
 
 
TABLE 6 Time-related indicators across frontline treatment milestones 
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3.10. Post-end of treatment toxicities / Sequelae 
Grade 3-4 toxicities/sequelae lasting after end of treatment were 
present in 96% patients (50/52; 5 unknown; one died short after the initial 
diagnosis). Main toxicities were heterogeneous; they are shown in Table 7. 
Neurological toxicities included motor sequelae (paresis/paralysis), 
cranial nerves palsy, polyneuropathy, ataxia, posterior fossa syndrome, and 
neurogenic bladder. Neurocognitive sequelae included learning difficulties 
and IQ loss.  
Endocrine toxicities included hypothyroidism, growth hormone 
deficiency, diabetes insipidus, adrenal insufficiency, malnutrition, and growth 
failure. 
Second malignancies included myelodysplastic syndrome, basal cell 
carcinomas and high-grade diffuse astrocytoma (described in a previous 
section). 
Other toxicities included epilepsy/seizures, hearing or visual 
impairment,  and renal tubulopathy. 
From 2008, the hospital’s Palliative Care Unit was created and 
supported patients with relapsed disease and those with severe disability. Out 
of the 42 patients diagnosed after its creation, 38% (16/42) were supported by 
the unit. 
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Grade 3-4 long-term toxicities Alive (n=31) Dead (n=21) 
Motor sequelae  16 (52%) 14 (67%) 
Other neurological sequelae  17 (55%) 12 (57%) 
Endocrine toxicities 13 (42%) 4 (19%) 
Neurocognitive sequelae  9 (29%) 3 (14%) 
Second malignancies 3 (10%) 1 (5%) 
Epilepsy/Seizures 2 (6%) 1 (5%) 
Hearing impairment 3 (10%) 0 
Visual impairment 0 1 (5%) 
 
TABLE 7 Grade 3-4 long-term toxicities 
 
 
 
3.11. Improvement opportunities and quality indicators 
The identified areas of improvement in the treatment of children and 
adolescents with medulloblastoma, and our subsequently proposed quality 
indicators are described in table 8. 
 
Areas of improvement Quality Indicators 
Diagnosis 
Quick referral after suspicion/diagnosis - Time to diagnostic MRI - Time to initial surgery 
Centralized diagnosis 
- % of centrally reviewed samples 
- % of samples with basic set of 
molecular markers 
Global strategy 
Inclusion in clinical trials 
- % of patients enrolled in clinical trials 
as frontline treatment 
- % of patients enrolled in clinical trials 
as salvage treatment 
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Standardization of treatments 
- Number of protocols/strategies 
followed within the same patient 
population 
- Number of patients receiving 
treatments off-label 
Treatment modalities 
Surgical outcome 
- % of patients achieving GTR 
- Number of deaths due to surgical 
complications 
Experience of surgical team - Number of patients/year - % of GTR after second-look surgery 
Rapid access to RT - Time to RT <40 days (% of patients) 
Access to novel RT modalities - % of patients receiving particle therapy 
Treatment delivery 
- Protocol deviations 
- % of patients with CT dose-intensity 
modifications 
- % of patients with CT time-intensity 
modifications 
Outcomes 
Survival - 5-year Overall Survival - 5-year Progression-Free Survival 
Toxicity - Supportive care guidelines - Treatment-related mortality 
Long-term and end-of-life care 
Long-term follow-up 
- Standardized follow-up assessments 
- % of patients with grade 3-4 
neurocognitive disorders 
- % of patients with grade 3-4 endocrine 
disorders 
Palliative care 
- % of patients receiving support from 
the local Palliative Care Unit 
- Time between engagement of the 
Palliative Care Team and death 
- % of patients deceased at home 
%: Percentage; CT: Chemotherapy; GTR: Gross Total Resection; HNJ: Hospital Niño 
Jesús; MRI: Magnetic Resonance Imaging; RT: Radiotherapy. 
 
TABLE 8 Areas of improvement 
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4. DISCUSSION 
 
Despite overall improvement in the outcome of children and 
adolescents with medulloblastoma over the last decades, mortality and 
morbidity rates are still unacceptably high, especially in patients with high risk 
features [93]. On top of the general effort to develop new treatments [43], there 
is wide room for improvement to deliver high-quality care at a 
local/institutional level. These pragmatic changes that would improve the 
management of children with medulloblastoma have a broad range of 
complexity. For instance, at a European level, there are ongoing initiatives such 
as QUARTET (“QUAlity and excellence in RadioTherapy and imaging for 
children and adolescents with cancer across Europe in clinical Trials”), which 
aims to build a radiotherapy quality assurance (RTQA) platform across all 
pediatric malignancies in Europe in trials [100]. It is constituted in partnership 
between SIOPe (European Society of Pediatric Oncology) and the EORTC 
(European Organisation for Research and Treatment of Cancer), and it will help 
implement RTQA programs in several SIOPe trials including SIOP-PNET 5 
(NCT02066220) for medulloblastoma. At a national level, the CNS Tumors 
Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP) 
has recently published a multi-center analysis of the management of non-
medulloblastoma CNS embryonal tumors in Spain, pointing out several 
aspects that could be improved: developing a common treatment strategy, 
ideally within international collaborative clinical trials, improving referral 
pathways and reference centers for treatment of complex and rare tumors, 
maximizing collaboration among pediatric oncology centers, and 
incorporating new biological markers and the new classification of embryonal 
CNS tumors [101]. These national and international initiatives are certainly 
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steps in the right direction, and they will hopefully contribute to improve the 
outcome of children with medulloblastoma and other complex CNS tumors. 
Beyond this, there are several aspects that could be addressed and 
improved at an institutional/local level. We have conducted this study at 
Hospital Niño Jesús in Madrid, Spain, a national referral center for pediatric 
oncology.  
Our pragmatic approach to this real-world cohort of children with 
medulloblastoma has highlighted the strengths and weaknesses in the 
management of these patients at a local level. The global outcome of the 
patients seems comparable to the results obtained in Spain and Europe. The 
5-year OS for the whole study population is 59% (95%CI 47-75%), which is 
similar to the most recent European available data for CNS embryonal tumors, 
with a 5-year OS of 59.0 (95%CI 49-67), and higher than the 5-year OS of 48% 
(95%CI 33-62) in Spain [6, 88].  (Of note: these data refer to the period 2005-
2007 for Europe and 2005-2008 for Spain, and include all embryonal CNS 
tumors; 5-year OS data for medulloblastoma only might be higher). It is 
important to point out that 21% of patients underwent frontline treatment at 
other institutions (different than HNJ) and were referred to HNJ after 
relapse/progression. This percentage is even higher (29%) if we include 
patients that were referred to HNJ after initial surgery. Moreover, there are 
some patients (5%) that only received aHSCT at HNJ. This heterogeneity on 
referral pathways potentially adds a selection bias, as more high-risk patients 
tend to be referred as opposed to standard-risk patients.  
Other positive remarkable findings are the fact that the treatment 
strategies are homogeneous within patients receiving frontline treatment at 
HNJ, which is not always granted among complex tumors treated outside 
clinical trials [101]; and the fact that the majority of deceased patients (78%) 
were managed by the local Palliative Care Unit at the end of life. Furthermore, 
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median time from diagnosis to surgery was four days, and median time from 
surgery to RT was 39 days, which falls within the international standards of care 
(40 days) and has proven to be a major prognostic factor [93]. Lastly, only one 
patient died as a direct treatment-related toxicity (surgical complication). 
 
In spite of the acceptable survival rates and of the positive findings, there 
are several aspects that could be improved at this institutional level. 
1. The retrieval of information from the medical records, mainly in 
paper format, is difficult due to several factors. The transition to 
digital records started slowly at HNJ in 2016; in the meantime, and 
especially for older records, the access to the original paper records 
can be challenging and adds additional burden to auditing our 
clinical practice.  
2. The retrieval of information about patients referred from other 
institutions proved to be challenging. 
3. There is no systematized database for treated cancer patients at HNJ. 
This is an important pitfall, especially in a national reference 
institution that provides oncological care for 100 new patients each 
year (4-6 of them with medulloblastoma).  
For sure, these limitations accessing medical records as well as 
missing data hinder the implementation of QA measures and of 
institutional clinical audits, which could certainly lead to an 
improvement in the overall management of the patients.  
4. Histological diagnosis is provided at the local pathology department, 
with no central review of the samples. While complex cases are 
referred to other institutions for review, this is not performed in a 
systematized way. However, the situation has improved since the 
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opening of the SIOP-PNET 5 trial at HNJ in 2016, in which pre-
treatment central pathology review is mandatory. 
5. There is a delay between the advances in the biological knowledge 
about medulloblastoma and the translation of this knowledge into 
clinical practice. This is a problem common to other pediatric cancer 
types and to other rare diseases [102] and is yet to be addressed at 
leading institutions such as HNJ. While the four molecular 
medulloblastoma subgroups were formerly defined in 2011 [21], 
molecular markers were not implemented until January 2013 in the 
local pathology department. Since then, only 42% of the newly 
diagnosed patients had an available complete molecular profile. Of 
note: since 2016, eligible patients at HNJ are included in the clinical 
trial SIOP-PNET 5, facilitating the implementation of a basic 
molecular profile for all newly diagnosed patients.  
6. The frontline strategy for patients treated at HNJ was homogeneous 
throughout the risk groups. Nonetheless, few patients were included 
in the respective clinical trials, while most were treated following the 
protocols or publications of those trials. Furthermore, among the 
patients that had relapse/progression, only two (6%) were included 
in clinical trials and received novel therapies. This will certainly 
improve over the next years thanks to the growing network of the 
SEHOP and to the recent set up of the Clinical Trials Unit at HNJ [103], 
which is part of the ITCC (Innovative Therapies for Children with 
Cancer) consortium [104]. 
7. The size of the surgical rest is a well-known prognostic factor. 
However, in spite of over one third (36%) of the patients not 
achieving GTR on initial surgery, only four of them (19%) underwent 
second-look surgery (one of them achieving GTR). Although recent 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
94 
studies suggest that the prognostic benefit of increased extent of 
resection is attenuated after molecular subgroup affiliation is taken 
into account [19], maximum safe surgical resection remains the 
standard of care. 
8. Regarding RT practices in our study population, missing data 
impaired a more comprehensive review. While it has notably 
improved over the last five years, this is an area that needs further 
upgrading. Thorough collection of RT data (including RT plans and 
imaging) could lead to better reviews of the RT practices and to the 
implementation of a local RTQA program. Furthermore, equal access 
to novel RT modalities (e.g. proton therapy, IMRT, gamma knife) 
should be granted. 
9. Almost all patients (96%) are reported to have grade 3-4 long-term 
toxicities. However, the reporting of toxicities varies among areas. 
While motor/neurological and endocrine sequelae have a similar 
reported incidence compared with other series found in the 
literature, other toxicities such as hearing impairment and 
neurocognitive sequelae seem underreported [52, 55, 57]. A 
systematic neurocognitive evaluation program should be 
implemented to better define and address the needs of the 
survivors.  
10. While the quality of life (QOL) and the patient-reported outcomes 
(PROs) are gaining increasing importance in the cancer research 
community over the last decade [105–107], none of the patients 
included in our study underwent QOL assessment, neither during 
treatment nor during follow-up. From 2016, this has been improving 
thanks to the opening of the clinical trial SIOP-PNET 5, which includes 
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serial QOL assessments; an important step towards the optimization 
of psychosocial support for these patients.  
Some limitations of this study ought to be acknowledged. The 
retrospective nature of the study has magnified the problem of missing data 
(addressed in the previous points 1.-3.), making some important information 
inaccessible (especially regarding RT plans and lines of treatment provided 
outside HNJ). The lack of central pathology review has to be pointed out as 
well. The monocentric nature of this work makes the resulting sample size 
(n=58) inadequate for complex statistical analysis (e.g. multivariate analysis), 
and hence the conclusions derived from survival analysis should be handled 
carefully. On the other hand, the main aim of this review is to find aspects in 
the care of patients with medulloblastoma that can be improved at a local level, 
and in that regard, this monocentric approach to a referral institution such as 
HNJ serves its purpose in a very pragmatic way. The identified areas in need of 
improvement may be extrapolated to other pediatric oncology centers in 
Spain; nonetheless, a national review and a common strategy should be 
encouraged. The multidisciplinary team workflow already in place at HNJ, with 
a smooth and quick collaboration between all the cancer care providers 
(pediatric oncologists, surgeons, radio-therapists, nurses, psychologists, etc.) 
and strongly promoted by the weekly tumor board meetings, is a good model 
to be exported to other national centers.  
A further strength of this study is the long-term follow-up of the patients 
at HNJ; in spite of the majority of them coming from other parts of Spain, the 
median follow-up time of survivors was longer than five years. Moreover, this 
study analyses a real-world data cohort which allows to draw conclusions that 
go beyond those driven from clinical trial cohorts. Hopefully, this study will help 
to better understand the gap between clinical trials and real-world survival and 
to find ways to reduce this gap. 
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The main conclusion of this work is that there is widely room for 
improvement at an institutional level in the management of children and 
adolescents with medulloblastoma in Spain. Although the survival rates of 
children treated at HNJ are comparable to those achieved across Spain and 
Europe, there are several specific aspects that could be optimized. This study 
has served to identify several areas of improvement and to propose concrete 
and affordable measures. The first step could be to implement a quality 
assurance system; this includes creating a database for the systematic 
collection of patients’ data and performing regular clinical audits. In lack of 
internationally validated quality indicators for the management of pediatric 
patients with CNS tumors, the quality indicators proposed in our study may be 
of help.  Other measures that can benefit patients include: maximizing the 
inclusion of patients in international clinical trials and expanding the Clinical 
Trials Unit; establishing a central pathology review; accelerating the translation 
of the new molecular knowledge into daily practice through the use of up-to-
date biological markers; and implementing a neurocognitive and QOL 
evaluation program. 
Beyond the local level, there is a strong need for collaboration and 
networking in the treatment of complex CNS tumors such as medulloblastoma. 
Single institutions, especially reference centers, will benefit from an enhanced 
national network and from the implementation of well-structured referral 
pathways; and vice versa, the national (and European) network would benefit 
from using a network of institutions with good practices, high quality data and 
regular auditing of clinical data.  
Hopefully, our proposed measures will contribute to the improvement 
of outcomes for children and adolescents with medulloblastoma in the near 
future, starting at a local level and beyond.  
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IV. RESEARCH PROJECT #2: 
 
 
 
Management and outcome of children and 
adolescents with non-medulloblastoma CNS 
embryonal tumors in Spain: Room for 
improvement in standards of care 
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1. INTRODUCTION  
 
Embryonal neuroectodermal tumors of the CNS that are not 
medulloblastoma, previously called central nervous system primitive 
neuroectodermal tumors (CNS-PNET) and pineoblastomas (PB) [7, 8], are rare 
and aggressive embryonal tumors with poor outcome. Together, they account 
for less than 5% of childhood CNS tumors [2, 6]. 
 Due to their low incidence and to their insufficiently known biology, 
these tumors have been historically treated with protocols for high-risk 
medulloblastoma. However, there is growing evidence from molecular genetic 
studies that CNS-PNET, PB, new entities such as embryonal tumors with 
multilayered rosettes (ETMR), and medulloblastoma are different entities [59–
62]. This knowledge has already been reflected in the most recent 2016 World 
Health Organization (WHO) classification, that differentiated pineoblastoma 
from ETMR, C19MC-altered, and has created a “wastebasket” category of CNS 
embryonal tumors, NOS [8]. There seems to be clinical differences as well, with 
CNS-PNET/PB showing a more aggressive behavior and lower survival rates 
than medulloblastoma [73]. 
Despite the achieved improvement over the last years, the historical 
series show a 5-year overall survival (OS) of 18-38% [71, 74, 76, 108, 109]. In 
addition, when practice-changing strategies obtained from clinical trials in 
particular institutions are brought to general clinical practice, the results, i.e. 
real-world data, are recurrently disappointing [9].  
 The two main aims of this study are: to present a tumor-specific, national 
real-world data cohort (as opposed to clinical trials data) of children and 
adolescents with CNS-PNET/PB and to identify weak points and quality 
indicators that can be implemented to improve the still dismal outcome of 
these patients. 
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2. METHODS 
 
2.1. Patient identification 
 Major Spanish pediatric cancer hospitals, all of them with one member 
participating in the CNS Tumors Group of the Spanish Society of Pediatric 
Hematology and Oncology (SEHOP), were contacted. At each site, the 
hospital’s clinical database was queried for all patients with the diagnosis of 
“PNET”, “pineoblastoma”, “ependymoblastoma” and “Embryonal Tumor with 
Abundant Neuropil and True Rosettes” (ETANTR) between 2005 and 2014.  
(Note: At the beginning of data inclusion, the old terminology “PNET” was 
being used. Subsequently, the new 2016 WHO classification was published, 
removing the term ¨PNET” and reclassifying those tumors into the subtypes 
“ETMR, C19MC-altered”, “ETMR, NOS”, “Medulloepithelioma”, “CNS 
neuroblastoma”, “CNS ganglioneuroblastoma”, and “CNS embryonal tumor, 
NOS” [8]. The old terminology was used for this study.)  
 The Clinical Research Ethics Committee from Hospital Niño Jesús 
centrally approved the study. Local institutional approval for retrospective 
chart review was sought at all participating hospitals. 
 
2.2. Eligibility 
 Inclusion criteria were histologically confirmed diagnosis of CNS-
PNET/PB (according to the 2007 WHO classification [7]), ependymoblastoma 
and ETANTR, age 0-21 years at diagnosis, time of diagnosis between January 
2005 and December 2014, and fully available clinical data. For this study, 
available pathology reports were reviewed by an experienced neuro-
pathologist. 
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2.3. Record review 
 Data collected included demographic information, age and symptoms 
at diagnosis, extent of disease, extent of surgical resection, initial treatment 
strategy and its deviations and toxicities, as well as information regarding 
relapses and salvage treatments, if any, and outcome. 
 Size and location of primary tumor was assessed by the diagnostic MRI.  
Size of the primary tumor was measured in three dimensions. Standard Chang 
M-stage classification as established for medulloblastoma was used. [15]. 
Extent of resection was determined from the operative report as well as 
post-operative MRI. Gross total resection (GTR) was defined as no evidence of 
enhancing tumor on post-operative imaging. Subtotal resection (STR) was 
defined as any surgical resection less than GTR. A third designation, “biopsy 
only”, was given to patients whose operative note included that text. 
Chemotherapy (CT) modifications were defined as time-intensity 
deviations (delay >1 week between cycles), dose-intensity deviations (>10% 
dose reduction of CT agents) and/or CT agents withdrawal.  
Toxicities were evaluated following the National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE), v.4.03 [96]. 
Patients were stratified regarding whether they received radiotherapy as 
first-line non-surgical treatment (radiation-inclusive strategies), as opposed to 
those who followed radiation-sparing baby-brain strategies. 
 
2.4. Statistical analysis 
Time to progression was calculated from the date of first treatment to 
the date of radiologic progression. Endpoint of analysis for all patients was 
either the date of last follow-up or date of death.  
Survival was estimated using the Kaplan-Meier method, and exact log-
rank test was used for comparisons of survival in different groups. Progression 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
102 
free survival (PFS) was defined as the date of first treatment to date of first 
progression or relapse, or the date of last follow-up. Overall survival (OS) was 
defined as the date of first treatment to death of any cause or the date of last 
follow-up. Log-rank test was applied to identify significant prognostic factors 
for PFS and OS. 95% confidence intervals (CI) were provided. The significance 
level was fixed for all P values under 0.05. Analysis was performed using the 
SPSS software®, version 21.0, and the free software R, version 3.4.0. The ability 
to do multivariate analysis was limited due to the small sample size and was 
therefore not performed.  
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3. RESULTS 
 
3.1. Patient demographics and presentation 
Eight major institutions (out of all nine contacted, belonging to the CNS 
tumors group of the SEHOP) contributed to this study and included all their 
potential patients: 52 patients aged 0-21 years with local histological diagnosis 
of CNS-PNET/PB were registered. Nine patients were excluded from this 
analysis: three patients who did not meet all inclusion criteria on central review 
and six patients whose medical records were incomplete (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1 Flow diagram of patients 
 
Final n: 
43 Patients 
9 Excluded Patients 
 
- 6 Incomplete Medical Records 
- 3 Failing inclusion criteria 
24 treated with radiation-
sparing protocols 
52 Registered 
Patients 
19 treated with radiation-
inclusive protocols 
19 Dead  5 Alive  9 Dead 10 Alive  
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That yielded 43 eligible patients (22 male, 21 female). Demographic and 
diagnosis characteristics are shown in Table 1. The median age at diagnosis 
was 3.6 years (range 0.01-14.70). None of the patients had relevant medical 
history or identified genetic disorders.  
At presentation, symptoms were heterogeneous, with headache, 
vomiting or irritability/somnolence occurring in >81% of patients (Table 1). 
Median duration of the main symptom was 2 weeks (range 0-12). 
Median longest diameter of primary tumor was 60.5 mm (range 21.0-
95.0).  
At diagnosis, 12 patients (28%) presented with metastatic disease. One 
patient was classified as M1 (2%), six as M2 (14%) and five as M3 (12%). 
 
3.2. Biological features 
Histology was pineoblastoma (n=4, 9%), ependymoblastoma (n=2, 5%), 
ETANTR (n=3, 7%), ganglioneuroblastoma (n=1, 2%) and PNET (n=33, 77%). 
Full pathology reports were reviewed in light of the 2007 WHO criteria for 36 
patients (84%). 28 cases (78% of those with available pathology report) had all 
required information to confirm the diagnosis of CNS-PNET and eight cases 
(22%) had insufficient descriptive information to confirm the diagnosis of CNS-
PNET. 
As a result of this study, a subsequent retrospective molecular analysis 
of archival tumor samples available for this patient cohort (22/43, 51%) has 
been started in collaboration with European reference centers. The preliminary 
results of the DNA methylation profiling suggest that 55% (12/22) samples 
were misdiagnosed as CNS-PNET: three medulloblastomas, two 
glioblastomas, an ATRT, an Ewing sarcoma, a ganglioglioma, a glioma of 
uncertain malignancy, an ependymoma, a central neurocytoma, and one 
undetermined. 
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Characteristics No. % 
Patient and tumor characteristics 
Sex 
  Male 22 51 
  Female 21 49 
Age 
  <3 years 16 37 
  >3 years 27 63 
Histology 
  CNS-PNET 33 77 
  Pineoblastoma 4 9 
  Ependymoblastoma 2 5 
  ETANTR 3 7 
  Ganglioneuroblastoma 1 2 
M Chang Stage 
  M0 31 72 
  M1 1 2 
  M2 6 14 
  M3 5 12 
  M4 0 N/A 
Symptoms at diagnosis 
  Headache 25 58 
  Vomiting 22 51 
  Neurocognitive symptoms 15 35 
Frontline treatment 
Global strategy 
  Head Start II [34] 8 19 
  PNET 4 [98] 5 12 
  HART-Milan [28] 3 7 
  COG-ACNS 0334 [NCT00336024] 3 7 
  HIT (<3 years old) [71] 2 5 
  St Jude MBL 96 2 5 
  Others 20 47 
Treatment modalities 
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  Surgery 43 100 
      Gross total resection 23 53.5 
      Subtotal resection 7 16.5 
      Biopsy only 13 30 
  Radiotherapy upfront 19 44 
      >4 years old 16 37 
      3-4 years old 3 7 
      Only local field (focal RT) 1 2 
      Local field + CSI 18 42 
      No RT upfront 24 56 
  Chemotherapy   
      Systemic CT 37 86 
      Intrathecal CT 8 23 
      aHSCT 14 33 
      No CT upfront 6 14 
 
 
aHSCT: Autologous Hematopoietic Stem Cell Transplantation; CNS-PNET: Central 
Nervous System Primitive Neuroectodermal Tumors; ETANTR: Embryonal Tumor with 
Abundant Neuropil and True Rosettes; CSI: Craniospinal irradiation; CT: 
Chemotherapy; RT: Radiotherapy. 
 
TABLE 1 Baseline and frontline treatment characteristics 
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3.3. First line treatment 
3.3.1. Global strategy 
Frontline treatment strategy was very heterogeneous with 17 different 
approaches. The most frequently used protocols were Head Start II (n=8, 19%), 
SIOP-PNET 4 (n=5, 12%) and HART-MILAN (n=3, 7%), all of them originally 
designed for patients with medulloblastoma [28, 34, 98, 110, 111]. In spite of 
this disparity of strategies, all of them included surgery with the widest possible 
resection and craniospinal irradiation (CSI) whenever the patient’s age and 
condition allowed it. Patients were treated upon two main categories, 
radiation-sparing and radiation-inclusive protocols, depending on their age, 
with a cut off between 3 and 4 years; the use of radiotherapy (RT) on first line 
applied for older patients, and sparing or delaying radiation for younger 
patients. Following this classification, 24 patients (56%) were treated with 
treatment strategies designed to avoid radio-induced brain damage, whereas 
19 patients (44%) were treated with radiation-inclusive regimens.  
The most important differences in treatment strategies were found 
among chemotherapy regimens, especially on their drug doses and time-
design. Another extended first-line modality was aHSCT, with up to a third of 
patients (n=14, 33%) undergoing transplant (eight within radiation-sparing 
strategies, six within radiation-inclusive strategies). 
 
3.3.2. Surgery 
All patients underwent surgery on the first-line approach. Median time 
to surgery (from MRI diagnosis) was three days (range 0-36). GTR was 
accomplished on first surgery in 19 patients (n=43, 44%) and on second-look 
surgery in four patients (n=43, 9.5%). In seven patients (16.5%) only STR was 
achieved, despite five of them undergoing a second-look surgery.  
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Twenty patients (47%) showed grade 3-4 severe surgical complications: 
cranial nerves paresis/paralysis (n=7, 16.5%), other motor symptoms such as 
hemiparesis, limb weakness or hypotonia (n=11, 26%), infection (n=2, 5%). Five 
patients (12%) underwent second surgery due to complications derived from 
the first one. Two patients (5%) died due to brain hemorrhage during the 
second surgery, both performed as a second-look attempt; both patients were 
neonates. 
 
3.3.3. Radiotherapy 
RT was administered to 19 patients (n=43, 44%) as frontline treatment. 
Four children older than 4 years did not receive RT on first line: in one patient, 
due to his palliative situation; in the other three, due to radiation-sparing 
treatment protocols (Head Start II [34] and COG-ACNS0334 -NCT00336024-). 
Median total dose was 55.8 Gy (range 54.0-62.0). Median CSI dose was 23.4 
Gy (range 22.4-39.7) and median dose of the boost to the primary tumor was 
26.5 Gy (range 18.0-32.4). One of the patients (8-year-old) received focal RT 
without CSI. Median duration of RT was 43 days (range 32-59). Most patients 
(n=12, 63%) presented acute toxicity (first three months after RT start date), but 
this consisted mainly of grade 1-2 radiodermatitis (n=8, 67% of patients with 
toxicity). Three patients had grade 3 toxicities (pancytopenia, vomiting). All 
patients completed the full planned radiation dose. 
 
3.3.4. Chemotherapy 
Most patients received CT as part of their first line treatment (n=37, 
86%). When combined with irradiation (n=18), CT was administered as 
consolidation after RT in 12 (67%) patients, and prior to RT in six (33%) patients. 
Intrathecal CT was used in 23% of the patients (n=8/35). Median duration of CT 
treatment was 4.3 months (range 0.1-14.5). Up to 63% of patients (n=22/35, 2 
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unknown) required significant modifications on the original CT plan due to 
chemotherapy-related toxicities. Forty-nine percent (n=17/35) had time-
intensity modifications, with at least one significant delay on a CT-cycle start. 
Twenty-six percent (n=9) had dose-intensity modifications, with at least one CT 
agent dose reduction (min. 20% over initial dose). In 23% (n=8) of the patients 
at least one CT agent had to be withdrawn or substituted with another agent 
(e.g. carboplatin for cisplatin due to tubulopathy).  
 
3.3.5. Autologous HSCT 
Autologous HSCT was performed as part of the first-line strategy on 14 
patients (33%), in five (35%) of them in combination with irradiation. It followed 
RT as consolidation treatment in three (21%) patients, and was administered 
prior to irradiation in two (14%). Most of them underwent a triple or quadruple 
tandem transplantation (n=11/14, 79%) [112]. Patients were on situation of 
complete response (n=7, 50%) or partial response (n=7, 50%) prior to starting 
aHSCT. One of the patients went from partial response to complete response 
after aHSCT, one went from partial response to progressive disease, and the 
rest had the same disease status after aHSCT. Nine patients (64%) had grade 
3-4 post-HSCT toxicities aside from hematologic toxicities. 
 
3.4. Toxic mortality 
Two patients (5%) died due to toxicity, both during surgery. No patients 
died due to CT or RT toxicity. During follow-up, no patients developed second 
malignancies or died of therapy-related causes after completion of treatment.  
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3.5. Relapse and patterns of failure 
Twenty-eight (65%) patients experienced relapse. Median time to first 
relapse was 6.7 months (range 2.3-44.9). Nine (32%) patients had received RT 
as frontline treatment. 
Eight patients (n=43, 19%) had a second relapse and three (7%) a third 
relapse. 
First relapse was local in 14/28 patients (50%), metastatic in eight 
patients (29%), and both local and metastatic in six patients (21%).  
 
3.6. Salvage treatment on first relapse 
Surgery was used on 13/28 patients (46%), but only in 4/13 patients 
(31%) GTR was achieved (one of them needing second-look surgery). RT was 
used on 10/28 patients (36%). Only one of them had received RT previously as 
first line approach and had re-irradiation. 15/28 patients (54%) were treated 
with chemotherapy, nine of them (60%) with diverse irinotecan-temozolomide 
regimens [99] and two with metronomic regimens [113]. Two patients also 
received intrathecal chemotherapy and another two underwent aHSCT. Only 
one patient (n=28, 4%) received novel agents (bevacizumab and rapamycin), 
both used off-label. There are three survivors among the relapsed patients, 
with a follow-up of 1.8, 2.4 and 3.5 years. The first two patients had local 
relapse; both underwent surgery, achieving GTR. The third patient presented 
both with local and metastatic relapse (M2); he did not undergo surgical 
resection. All three received first RT at the time of salvage therapy, and all three 
received adjuvant chemotherapy as well. 
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3.7. Outcomes and prognostic factors  
Median follow-up for survivors was 3.5 years (range 1.7-9.3). See Figure 
2 with a swimmer survival plot representing the study population.  
For the whole population, 3-year PFS was 31.9% (95%CI 17-47%) and 3-
year OS was 35.1% (95%CI 20-50%), as shown in Fig. 3. 
Age less than 3 years at diagnosis, not achieving GTR and not having 
been irradiated in first line were variables significantly associated with worse 
outcome in the univariate analysis (p<0.05), with impact on both PFS and OS 
(Table 2). 
 
3.8. Neurocognitive outcome 
The study did not include routine neurocognitive assessments due to its 
retrospective nature and hence, these toxicities are likely under-reported. 
Grade 3-4 long-term neurocoginitive toxicities/sequelae were present 
in 11/15 (73%) survivors, all of them needing intensive physical and 
neurocognitive rehabilitation treatment. These moderate-severe sequelae 
included hearing (27%) and visual impairment (20%), learning difficulties 
and/or IQ loss (27%), epilepsy (20%) and other neurological deficits, e.g. 
neuropathy (33%).  
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FIGURE 3 Swimmer survival plot for all series. 
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A 
 
B 
 
 
FIGURE 3 Kaplan-Meier Curves for all series. 
A, Overall Survival. B, Progression Free Survival 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
114 
Variable 3-year PFS  
(95% CI) 
Log-Rank 3-year OS  
(95% CI) 
Log-Rank 
Gender:  
Female vs Male 
25% (3-48%) vs 
36 % (16-57%) 
p=0.15 23% (1-45%) vs 
40% (19-61%) 
p=0.054 
Duration of 
symptoms (<2 weeks 
vs >2 weeks) 
25% (0-50%) vs 
34% (15-52%) 
p=0.38 15% (0-40) vs   
38% (18-57%) 
p=0.51 
Age at diagnosis 
(<3 years vs >3 years) 
11% (0-30%) vs 
42% (23-61%) 
p=0.021 10% (0-27%) vs 
45% (25-65%) 
p=0.021 
Tumor primary site 
(Supratentorial vs 
Other sites) 
39% (19-59%) vs 
21% (0-43%) 
p=0.13 37% (17-57%) vs 
21 (0-43) 
p=0.1 
Disease extension 
(M0 vs M1-4) 
37% (19-55%) vs 
18% (0-41%) 
p=0.14 38% (19%-57%) vs 
18 (0-41%) 
p=0.03 
Histology (PNETs vs 
Other histologies) 
29% (12-45%) vs 
42% (24-76%) 
p=0.4 31% (14-49%) vs 
39% (4-73%) 
p=0.5 
Extent of resection 
(GTR vs Non-GTR) 
42% (21-62) vs 
18% (0-37%) 
p=0.03 41% (19-62%) vs 
24% (3-44%) 
p=0.04 
Radiotherapy 
(Yes vs No) * 
57% (34-80%) vs 
7% (0-20) 
p=0.00 57% (33-80%) vs 
11% (0-26%) 
p=0.001 
 
GTR: Gross Total Resection; OS: Overall Survival; PFS: Progression-Free Survival; 
PNET: Primitive Neuroectodermal Tumors. 
 
In bold letters, those comparisons that reach statistical significance (p<0.05) 
 
* The distinction between patients depending on whether they received radiotherapy 
as frontline treatment (yes vs no) is equivalent to the distinction between patients 
treated with radiation-inclusive protocols vs patients treated with radiation-sparing 
protocols, respectively. 
 
 
TABLE 2 Three-year Progression-Free Survival and Overall Survival according 
to different baseline variables 
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4. DISCUSSION 
 
 Despite general improvement in the outcome of children with CNS 
tumors over the last decades, unacceptable mortality rates in patients with the 
formerly called PNET persist [71, 74, 76, 108, 109]. 
 In addition to their low incidence and biological aggressiveness, these 
tumors have remained in the shadow of medulloblastoma. Instead of 
displaying specific approaches, PNET/PB have been historically included in 
medulloblastoma clinical trials [28, 34, 71, 98, 110, 111]. 
 Moreover, lack of biological understanding of PNET adds to the critical 
deficiency in specific and novel treatment strategies. Recent molecular genetic 
studies [62] are extending our knowledge on these tumors, but we are still far 
from being able to translate this learning into the clinic. Furthermore, these 
studies suggest that a large proportion of PNET (up to 61% according to Sturm 
et al.) are being misdiagnosed under conventional histopathological criteria 
and are, in fact, high grade gliomas, ependymomas, or other tumors. This 
seems to be in agreement with the preliminary results of the DNA methylation 
profile of the available samples in our study, with 55% being reclassified to 
entities different than PNET. 
    
 We conducted this study to establish how children with non-
medulloblastoma embryonal CNS tumors (so called supratentorial PNET and 
pineoblastoma) have been managed over the last decade in Spain and identify 
areas of improvement.  
 Survival data in our study show a 3-year OS of 35.1% (95%CI 20-50%); in 
children <3 years this drops to 10% (95%CI 0-27%), whereas in children >3 
years it is 45% (95%CI 25-65%). These results are close to a similar population-
based study performed on UK (National Registry of Childhood Tumours –
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NRCT-) [9], where the authors described a 5-year OS of 32.5% for PNET. Our 
results are close as well to a similar study conducted by the Canadian Pediatric 
Brain Tumor Consortium [75], with a 4-year survival of 37.7%. However, they 
are far from US survival data (NCI’s Surveillance, Epidemiology, and End 
Results –SEER-) reflected on the same study, with a 5-year OS of 57.4%, which 
was conducted an earlier decade than ours (1996-2005). Of note, our study 
represents the practice of eight large institutions in our country, all having a 
pediatric oncologist participating into the CNS tumor group of the national 
Society. According to the national tumor registry (RETI), there are 
approximately five to six new cases of CNS-PNET per year in Spain. Our study, 
spanning 10 years, would have provided data for more than 75% of all cases 
over that period, but might not reflect the overall nation-wide situation where 
more than 40 pediatric oncology units treat children and adolescents with 
cancer [88]. The lack of a central pathology review is another limitation of the 
study; nevertheless, we put the accent on reporting the current situation with 
real-world data about clinical outcomes without further delays.    
 When compared to results obtained from clinical trials, the gap to our 
real-world data is widened. For instance, young children enrolled on the 
original Head Start I and II trials (the most frequently applied treatment strategy 
in our study) had 5-year EFS and OS of 39% (95%CI 24-53%) and 49% (95%CI 
33-62%), respectively [73].  
This recurrent gap between clinical trials and real-world survival reflects 
the need for collaboration through international multi-centric trials. Part of this 
difference can be explained by the strict patient selection of trials. However, it 
has been repeatedly pointed out in the literature that the recruitment into 
clinical trials improves the outcomes when compared to unselected 
populations treated at the discretion of the clinician [4, 9, 29]. Since none of 
the 43 patients included in this study were recruited into a clinical trial (neither 
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on first line treatment nor at relapse), this is certainly a point that could be 
improved. Beyond that, with 17 different first-line strategies, the first step 
towards improvement should be, in our opinion, to establish a common 
national strategy for the treatment of these patients.  
 In the absence of internationally accepted quality standards for 
treatment of children with CNS tumors, the search for specific aspects to be 
improved is challenging. This report suggests the importance of several 
factors: Firstly, attention should be paid to time from initial symptoms to 
diagnosis. In our study, the median of this interval was two weeks (range 0-12), 
a good result when compared to data reported for CNS tumors in other 
countries (Germany 24 days, Switzerland 60 days, UK 100 days) [9, 114, 115]. 
While different studies have not demonstrated a prognostic impact of time to 
diagnosis, it remains important to ensure rapid initial diagnosis [116–119].  
Also, our report shows that 74% of patients receive surgery within less than a 
week. However, of the 19 patients with irradiation planned upfront, only 42% 
received radiotherapy within 49 days of first surgery.  
Secondly, extent of resection is a well-known prognostic factor, also 
reflected in our study, where the experience of the neurosurgical team is key. 
In our study only half of the patients (23/43) achieved GTR. In this sense, 
national initiatives such as the creation of reference centers for complex 
neurosurgery [120] are positive and its impact will be evaluated in the future.  
 Thirdly, radiotherapy is another crucial factor impacting patients’ 
outcome, but its association with long-term morbidity, particularly in young 
children, is the major limitation. Hence, postsurgical radiotherapy deferral is 
common practice in children younger than 3 years, but it remains controversial 
in older children, especially in the “grey zone” 3-4 years, leading to disparity of 
criteria among scientific groups and institutions [121]. There were four children 
older than 4 years in our study that did not undergo RT as first-line treatment. 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
 
118 
In one of them this was due to his palliative situation, and he passed away soon 
after diagnosis. The other three were treated using protocols designed for 
young children (Head Start II [34] and COG-ACNS0334 -NCT00336024-). All 
three underwent RT on first relapse, but only one of them was rescued. 
 Fourthly, there are no established standards to quantify major toxicities, 
toxic deaths and modifications in chemotherapy time and dose intensity. These 
treatment protocols have potential significant toxicities and this study will serve 
as a baseline to measure new indicators prospectively.   
  
The main conclusion of this work is that although we benefit from a well-
established health care system in Spain, there is a strong need for collaboration 
and networking in the treatment of complex CNS tumors such as PNET/PB. The 
efficacy of the primary care system is reflected in our study in the fast diagnosis 
of these patients. Survival rates of children with PNET/PB are far from the rates 
obtained in international clinical trials and a common therapeutic strategy is 
lacking. This study has served to identify specific aspects to improve in the care 
of patients with CNS-PNET, namely developing a common treatment strategy, 
ideally within international collaborative clinical trials, improving referral 
pathways and reference centers for treatment of complex and rare tumors, 
maximizing collaboration among pediatric oncology centers, and 
incorporating new biological markers and the new classification of embryonal 
CNS tumors. As a result of this study, a subsequent retrospective molecular 
analysis of archival tumor samples available for this patient cohort has been 
started in collaboration with European reference centers. Hopefully this will 
lead to improved outcomes for children with CNS-PNET in the near future.   
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V. RESEARCH PROJECT #3: 
 
 
Past, present and future of radiotherapy quality 
assurance in pediatric CNS tumors:  
A European perspective 
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1. INTRODUCTION 
 
The improved survival rates of pediatric patients with CNS tumors over 
the last decades lead to a growing concern about long-term sequelae and the 
quality of life of the survivors [122]. Radiotherapy (RT) continues to be a 
cornerstone in the treatment of pediatric brain tumors, including embryonal 
tumors (e.g. medulloblastoma and the previously called primitive 
neuroectodermal tumors –PNETs) [71, 76, 98, 109]. However, the potential 
long-term sequelae of CNS irradiation are well known, such as neurocognitive 
deficits, growth impairment and endocrine toxicities [30–33, 123]. 
Therefore, minimizing the adverse events and the collateral damage of 
radiotherapy to the surrounding healthy brain tissue is one of the big 
challenges of modern radio-oncology [124]. New and more advanced RT 
techniques and equipment (intensity modulated radiation therapy -IMRT-, 
particle therapy, gamma knife, etc.) have improved the outcome of children 
with brain tumors by tackling this issue, at the price of growing complexity and 
the need for highly specialized centers [111, 121].  
These advanced techniques are the result of combining CNS tumor 
imaging with technology to plan and deliver radiation, the so called conformal 
RT. Through conformal RT, the radiation dose is targeted to the tumor, 
minimizing the dose to normal brain structures and hence reducing long-term 
side effects [125]. Some examples of conformal RT used for the treatment of 
pediatric CNS tumors are three-dimensional conformal RT, stereotactic RT, 
IMRT and proton beam RT, also named particle therapy. Regarding the latter, 
particle therapy (PT) is a growing radiation modality due to the characteristic 
dose distribution of the proton beam (Bragg Peak phenomenon), which is able 
to concentrate high doses to the tumor volume while delivering near-zero 
doses to non-target organs, i.e. sparing normal tissue [126].  
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In this highly complex technical setting, quality assurance (QA) 
programs and quality control are essential, considering that deviations in RT 
can result in increased morbidity and mortality. An example of this is provided 
by a study of the French Society of Pediatric Oncology (SFOP), in which the RT 
records of 174 pediatric patients with medulloblastoma were reviewed [127]. 
The number of major deviations in RT treatment was found to be strongly 
correlated with the risk of tumor relapse. The authors concluded that the 
quality of medulloblastoma RT technique is strongly correlated with outcome, 
and that pretreatment central QA review or standardized computer-designed 
blocks would improve survival to an extent equivalent to that attributed to 
adjuvant chemotherapy. 
However, the implementation of radiotherapy quality assurance (RTQA) 
systems is not yet universally achieved. Moreover, scanning the current 
practices of radio-oncologists and the existing RT resources at a supra-national 
level constitutes a major challenge. Lievens et al. recently achieved to draw an 
accurate picture of these practices and resources in Adult Oncology, but not 
without difficulty and in the frame of a long-term international cooperative 
project (HERO) [128, 129]. A similar pediatric-specific project is currently being 
carried out by Demoor-Goldschmidt et al. in the frame of a SIOPe European 
study, with the first results highlighting the difficulties to obtain accurate and 
complete data [92]. 
 
In order to analyze the situation of RTQA in the treatment of CNS tumors 
in Europe, this chapter comprises three pieces of work: 1) Literature review of 
RTQA in pediatric CNS tumors; 2) Review of RTQA aspects in past and current 
European collaborative trials; and 3) An international survey for radiation 
oncologists and pediatric oncologists about RTQA practices in Europe 
conducted in 21 European countries. 
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2. PAST AND PRESENT 
 
2.1. Current status of RTQA in pediatric CNS tumors in Europe 
 
Some important steps have already been taken regarding the definition 
of the minimal standards of care for pediatric cancer patients. The best 
example is the SIOPe (European Society of Pediatric Oncology) guideline, a  
consensus document describing the minimum quality requirements for a 
pediatric oncology facility [83].   
However, in the field of pediatric radiation oncology, there seems to be 
a lack of international QA guidelines when it comes to specific treatment 
modalities for a given pediatric tumor. While some RTQA programs are in 
place, they are so far implemented in a limited number of European countries 
and mostly limited to clinical trials. For instance, in Italy a centralized 
retrospective review system was recently created with the purpose of 
preparing for the upcoming clinical trials with RTQA demands (e.g. SIOP-
PNET5, NCT02066220). This interesting initiative is sponsored by a parent’s 
charity and uses the VODCA software (MSS, Switzerland) to review and assess 
protocol compliance of patient plans prior to irradiation [130]. 
 
Another finding of our review is that there seems to be a paradigm shift 
from retrospective to prospective RTQA over the last years. While in older 
studies retrospective quality assessments were the norm [127, 131–133], the 
most recent and relevant trials for pediatric brain tumors mostly include 
prospective RTQA programs (Table 1). The case of the SFOP medulloblastoma 
trials is noteworthy: A prospective RTQA review for craniospinal irradiation 
(CSI) was introduced in the M-SFOP 98 trial as a result of the conclusions drawn 
by the retrospective RTQA review of the previous M-SFOP 93 and SFOP.TC 94 
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trials (for standard and high-risk medulloblastoma, respectively) performed by 
Carrie et al. (already mentioned above) [127, 134]. The authors recommended 
the implementation of a prospective, real-time RTQA system following their 
findings that RT deviations have a negative impact on the outcome, with 
increased risk of tumor relapse. The subsequent central pretreatment RT 
review performed in the M-SFOP 98 trial was considered “not only feasible but 
useful” by the authors of the main publication, noticing a decrease in the 
number of relapses compared with the previous trial [134]. 
A further example of this paradigm shift in RTQA is given by the HIT-
SIOP PNET trials. In HIT-SIOP PNET 3, the RTQA review was performed 
retrospectively and published one year later than the trial’s primary publication 
[132, 135]. In HIT-SIOP PNET 4 however, RTQA was performed prospectively 
by some national groups, and retrospectively within a year for all patients [98]. 
Additionally, RTQA was considered mandatory to participate in the trial for CSI 
(optional for posterior fossa/tumor bed irradiation). In the ongoing HIT-SIOP 
PNET 5 trial (NCT02066220), RTQA is performed prospectively and is 
mandatory for CSI and all relapses. Furthermore, a QA exercise was performed 
before the opening of HIT-SIOP PNET 4, in which ambiguities in the draft 
protocol and areas of inter-clinician variation were found. Consequently, the 
protocol was revised and improved before the opening of the trial [136]. 
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Clinical trial Study 
Start 
Study 
End 
Tumor 
type 
RTQA Level of 
control  
Type of control Compliance Publication of 
RTQA aspects 
Main conclusion of 
RTQA publication 
COMPLETED TRIALS 
HIT-SIOP 
PNET 3 
[132, 135] 
March 
1992 
Jan. 
2000 
MB 
(M0-
M1) 
Yes Global 
(international) 
Retrospective UNK Separately from 
the primary 
publication (1 
year later) 
RT duration (<50 
days) impacts on EFS 
HIT-SIOP 
PNET 4 [98, 
136] 
 
Jan. 
2001 
Dec. 
2006 
MB 
(SR) 
Yes National Prospective for 
some national 
groups; 
Retrospective 
(within 1 year) 
for all patients 
Mandatory 
for CSI;  
Optional for 
posterior 
fossa/tumor 
bed 
QA exercise 
PRIOR to study 
opening 
Ambiguities in the 
draft protocol and 
areas of inter-clinician 
variation. 
Consequently, the 
protocol was revised 
and improved  
HART Milan 
[28] 
1998 2007 MB 
(MTX) 
Yes Local (only 
one institution 
administering 
RT) 
Retrospective NA Within primary 
publication (not 
detailed) 
“RT at the same 
institution following 
the local technical 
guidelines and 
quality control 
process” 
French M-
SFOP 98 
[134] 
Dec. 
1998 
Oct. 
2001 
MB 
(SR) 
Yes Global  Prospective for 
CSI, 
Retrospective 
for tumor bed 
boost 
Mandatory Within primary 
publication 
(somewhat 
detailed) and 
following pre-
existing 
national 
guidelines 
“Central 
pretreatment RT 
review is not only 
feasible but also 
useful” (no isolated 
frontal relapse 
occurred compared 
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with seven in the 
previous report) 
SFOP HR 
[137] 
Jan. 
1993 
June 
1999 
MB 
(HR) 
Yes Global Retrospective Mandatory Within primary 
publication 
(somewhat 
detailed) and 
following pre-
existing 
national 
guidelines 
EFS not statistically 
different for patients 
with no or one major 
deviation or for 
patients with more 
than one, possibly 
due to the low 
number of patients, 
but also because the 
impact of a deviation 
might be less when 
the dose is higher 
LGG 2004 
[138] 
 
April 
2004 
April 
2012 
LGG No * National Retrospective Mandatory 
(not clearly 
specified) 
No mention in 
primary 
publication 
NA 
HERBY 
[139] 
Oct. 
2011 
Feb. 
2015 
HGG UNK UNK UNK UNK No mention in 
primary 
publication 
NA 
ONGOING TRIALS 
HIT-SIOP 
PNET 5 
(NCT02066
220) 
June 
2014 
Open MB 
(SR) 
Yes National Prospective Mandatory 
for CSI and 
any relapse;  
Optional for 
posterior 
fossa/tumor 
bed 
NA NA 
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CSI: Craniospinal Irradiation; EFS: Event-Free Survival; EP: Ependymoma; HR: High Risk; IGCT: Intracranial Germ Cell Tumor; LGG: Low Grade 
Glioma; MB: Medulloblastoma; MTX: Metastatic disease; NA: Not Applicable; RT: Radiotherapy; RTQA: Radiotherapy Quality Assurance; SR: 
Standard Risk; UNK: Unknown. 
 
* Only data collection 
 
Of note: Treatment strategies for infants are not included (as they do not include RT). 
 
 
TABLE 1 RTQA aspects in recent clinical trial protocols for pediatric CNS tumors 
 
SIOP-EP-II 
(NCT02265
770) 
April 
2015 
Open EP Yes National Retrospective 
(within 4 
months) 
Mandatory 
(although 
not clearly 
specified) 
NA NA 
SIOP CNS 
GCT II 
(NCT01424
839) 
Oct. 
2011 
Open IGCT No * National Retrospective Mandatory 
(not clearly 
specified) 
NA NA 
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These examples of RTQA, although effective in the clinical trials setting, 
leave patients treated outside that context behind. This may widen the already 
existing gap between the outcome results obtained from clinical trials and the 
results obtained in real-world settings [9]. An example of this gap is given in 
the study by Vivekanandan et al., in which they reported the UK experience of 
using the HART-Milan strategy for the treatment of metastatic 
medulloblastoma [29]. In the real-world setting of 14 hospitals in the UK, the 
obtained results were far from those obtained in the original mono-centric trial 
(56% vs 77% 3-year OS). Furthermore, the confidence interval in the UK study 
(95%CI: 38%-71%) included the historical result of 40%. Therefore, the authors 
concluded that the reason they could not replicate the original trial results may 
be due to several factors: 1) statistical chance (expressed as the wide 95%CI 
for both series), 2) differences in patient characteristics, case selection, 
treatment delivery, and 3) the nation-wide implementation of a regimen 
previously tested in a single center. Additionally, a different group exploring 
neurotoxicity associated with this regimen in a separate UK cohort of patients 
discovered cases of severe and disabling neurotoxicity, which were not 
observed in the original trial [140]. The severe reported cases of myelitis and 
of other grade 3-4 CNS toxicities seemed to associate with the overlapping of 
upper cervical spine within posterior fossa boost volumes in conjunction with 
neurotoxicity associated with thiotepa [141, 142]. As a result of both real-world 
studies, the HART-Milan strategy was discontinued since 2014 in the UK, due 
to lower than expected survival rates and the concerns regarding neurotoxicity 
[29, 140]. 
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2.2. Survey: Current practices of radiation oncologists across Europe 
 
We have performed a survey about the current practices of RTQA in 
pediatric brain tumors across Europe with an “ask-the-expert” approach. The 
aim is to have a general perspective of the current situation and of the level of 
awareness of healthcare professionals on the available infrastructures and 
programs. We hereby present the results.  
 
2.2.1. Methodology 
One pediatric radiation oncologist and one pediatric oncologist of each 
European country (29 countries included: 23/27 official EU members, plus 
Israel, Norway, Serbia, Switzerland, Turkey and the UK) specialized in the 
treatment of CNS tumors were contacted in February 2018 by email and invited 
to complete an online 12-item questionnaire (Appendix 1). 
To compare the number of RT centers between countries, the total 
number was divided by the population of each country. Population data were 
obtained from the Central Bureau of Statistics for Israel and from Eurostat for 
the rest of the countries [143, 144]. 
 
2.2.2. Results 
Out of the 29 contacted countries, 21 (72%) responded and participated 
in the survey (Figure 1). A total of 48 experts were contacted: 18 (90%) out of 
20 contacted radio-oncologists responded to the survey; 15 (54%) of 28 
pediatric oncologists responded (Figure 2).  
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
130 
 
FIGURE 1 Participation across countries 
 
 
 
 
FIGURE 2 Type of respondents 
 
 
 
 
45%
55%
Pediatric Oncologists
Radiotherapists
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The number of public RT centers that treat pediatric patients with CNS 
tumors varies across countries, with a median of 3.7 (range 0.6-10.7) per 10 
million population (Figure 3).  
Most participants (67%, 22/33) agreed or strongly agreed that there is a 
known and well-established referral network for the RT treatment of pediatric 
patients in their respective countries. However, some showed concern that this 
network is “not official”, or still under construction, or only useful for patients 
treated within clinical trials (Figure 4). 
While only 19% (4/21) of the countries have a national pediatric 
radiotherapy society, 64% (21/33) of the participants responded that the level 
of involvement of pediatric radiation oncologists in the meetings and activities 
of the respective national pediatric oncology societies is “somewhat sufficient” 
or “sufficient”. The rest of the participants responded that the involvement is 
“somewhat insufficient” or “insufficient” in 30% (10/33) of the cases, and 
“Neither insufficient nor sufficient” in 6% (2/33) (Figures 5 and 6). 
Only 48% (10/21) countries have national consensus guidelines for the 
treatment of pediatric CNS tumors (Figure 7). National RTQA programs are in 
place in 33% (7/21) of the participating European countries (Figure 8). These 
programs are very heterogeneous: in Ireland, the participant responded that 
“all radical cases undergo prospective peer review performed by adult 
radiation oncologists”; in Belgium, the RTQA program works only for the 
clinical trials SIOP-PNET 5 and SIOP-EP-II so far; in Denmark, every RT dose 
plan is reviewed in a biweekly meeting with Swedish pediatric radiation 
oncologists; in France, the Aquilabâ system is used for all prospective trials; in 
Germany, the HIT network is in place for all pediatric CNS tumor studies; in the 
UK, there is a national RTQA team for all trials as well; and in the Slovak 
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Republic, there is an RTQA program that reviews the imaging system, planning 
system, irradiation equipment and plan implementation. 
Only three countries (14%; 3/21) have a central storage system for RT 
data in place (Figure 9). In all of them (Denmark, France and Germany), the 
complete DICOM radiotherapy plans are collected as part of the data. 
Pediatric patients with CNS tumors have access to a particle therapy 
facility in almost all (95%; 20/21) participating countries (nationwide or 
elsewhere, supported by the public health system) (Figure 10). In Turkey, 
particle therapy can be accessed abroad with the support of the national health 
system in some particular cases. 
Most participants (85%; 28/33) agreed or strongly agreed that all 
pediatric patients with CNS tumors are granted equal access to radiotherapy 
in their respective countries (Figure 11). Five respondents showed concerns 
that this might not be the case all over their respective countries (Israel, Italy, 
Spain, Switzerland and Turkey). For example, the Italian expert believed that 
patients from the South of Italy have worse access to well-trained teams. The 
Spanish expert thought that “most of the patients that need this treatment will 
get it, but probably the quality of this therapy and the expertise needed to 
provide it is not equal for all”. The Turkish expert believed that the 
geographical distribution of advanced pediatric radiotherapy centers is not 
well balanced: “Centers in the large cities of western and central Turkey 
capable of delivering high-quality radiotherapy, whereas conditions are not 
satisfactory in eastern parts of Turkey”. 
Almost all (91%; 30/33) consulted experts believe that the patients 
would benefit to a considerable or to a great degree from a European RTQA 
guideline for pediatric brain tumors (Figure 12 and Table 2). 
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The most relevant results of the survey are presented in the following 
figures and table (Figures 3-12; Table 2). 
 
 
FIGURE 3 RTQA centers for pediatric CNS tumors per country population. 
A, Number per 10 million population. B, Comparison between countries. 
A 
B 
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FIGURE 4 Existence of a well-established national referral network for the 
radiotherapy treatment of pediatric patients. A, Opinion among all 
participants. B, Map showing responses by country. Of note: In case of 
disagreement, the opinion of the radiation oncologist is highlighted in the 
map. 
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A 
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FIGURE 5 Existence of a national pediatric radiotherapy society 
 
 
 
FIGURE 6 Opinion about the level of involvement of pediatric radiation 
oncologists in the meetings and activities of their national pediatric oncology 
societies. 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Ped. Oncologists
Radiotherapists
Involvement of radiotherapists
Insufficient Somewhat insufficient Neither insufficient nor sufficient Somewhat sufficient Sufficient
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FIGURE 7 National guidelines for the treatment of pediatric CNS tumors. 
 
 
FIGURE 8 National radiotherapy quality assurance programs for the treatment 
of pediatric brain tumors 
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FIGURE 9 Central storage systems for radiotherapy data 
 
 
FIGURE 10 Access to a particle therapy facility (nationwide or elsewhere, 
supported by the public health system) 
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FIGURE 11 Existence of equal access to radiotherapy across all pediatric 
patients with CNS tumors at a national level according to the participating 
experts 
 
 
FIGURE 12 Potential benefit for the patients of a European RTQA guideline for 
pediatric CNS tumors according to the participating experts 
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Comments about the possible benefit of a European RTQA guideline 
“Unifying radiotherapy will ascertain high standards in Europe and may help less 
experienced centers. It will furthermore facilitate comparisons between different 
treatment studies.” 
“I think it would be great to define a kind of standard treatment that is good clinical 
practice for all children. The problem will be economically, the balance between 
evidence based good clinical practice and what is achievable/affordable in the 
individual countries.” 
“There is a strong international wish to harmonize structures, which is ongoing based 
on the QUARTET platform. Harmonized guidelines would to my understanding be 
helpful as a basis for definition of goals, measures and necessary resources.” 
“We are completely in favor of an European Network for Quality control in 
Radiotherapy, as well as in other issues, namely imaging, pathology and biology...  
Only with this kind of procedures we could treat patients with the state of the art. This 
is a particularly  important issue for small countries.” 
“It would be really useful to standardize protocols across the EU, as we recruit into the 
same trials, and would all be working from the same baseline then.” 
“We would be very happy to have such guidelines and some kind of supervision as 
well, especially for some difficult cases. This is true, in my opinion, for all small 
countries, as ours.” 
“I think that this should stay guidelines and not obligations. Patients would mainly 
benefit from better collaboration between the pediatric radiotherapists and between 
the pediatric radiotherapists and the pediatric oncologists on a national level.” 
“It would be a good initiative, however resources are scarce for this extra workload.” 
“Based on the QA experiences within PNET 5 a great benefit of QUARTET can be 
expected.” 
“Yes this would be something very helpful.  It is something that is being tried to be 
developed for some tumors (ependymoma) but not polished yet.” 
 
TABLE 2 Top 10 comments of the participating experts about the potential 
benefit for the patients of a European RTQA guideline for pediatric CNS tumors  
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3. FUTURE 
 
3.1. First steps and future development 
 
To address the above described challenges, first steps are being taken 
at different levels. At a national level, there are two prominent examples of 
good initiatives in European countries: in the Netherlands and in Belgium. In 
the Netherlands, there is a novel program for proton-therapy, “ProTraIT”, which 
is comprised within the Dutch Translational Research IT project (TraIT). This is 
a nationwide  IT infrastructure for data and workflow management targeted at 
the needs of translational projects [145]. It is within the frame of this wider 
platform that ProTraIT has been developed to centralize the data of all patients 
receiving proton-therapy (children and adults) and to perform model-based 
approach studies enabling individual double-planning, in which the best 
hypothesized outcome is chosen.  
While according to our survey only 29% (6/21) countries have an 
established national central storage system for RT data, this is already 
changing. A recent initiative in Belgium aims to implement a central record of 
the radiotherapy planning of every pediatric patient, in the frame of the Belgian 
Cancer Registry [146]. This long-term storage will eventually allow for a 
retrospective control of frontline treatments while no prospective check is 
foreseen. This is especially useful in the relapse setting, as it can improve the 
quality of the salvage radiotherapy; moreover, ensuring RT data are available 
at a very late stage is crucial to properly build multivariate toxicity models 
addressing long term Normal Tissue Complication Probability (NTCP). 
Accurate NTCP models are essential to create international treatment 
guidelines for optimal sparing of organs at risk. Both the Dutch and the Belgian 
initiatives are excellent examples of how existing research infrastructures can 
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be used for a downstream purpose, in this case RTQA for pediatric brain 
tumors. 
At a wider, European level, another major step is seen in the recently 
created European platform “QUARTET” (“QUAlity and excellence in 
RadioTherapy and imaging for children and adolescents with cancer across 
Europe in clinical Trials”), which aims to build a radiotherapy QA platform 
across all pediatric malignancies in Europe in trials [100]. It is constituted in 
partnership between SIOPe and the European Organisation for Research and 
Treatment of Cancer (EORTC). QUARTET will help implement RTQA programs 
in several SIOPe trials including SIOP-PNET 5 (NCT02066220) and SIOP-EP-II 
(NCT02265770). Although, in its current state, it only includes patients 
participating in clinical trials, it will eventually expand to patients treated 
outside of trials as well.  
The weaknesses of our study need to be acknowledged: 1) The 
performed literature review of RTQA in pediatric CNS tumors is, although 
extensive, not a systematic review; 2) The review of RTQA aspects in past and 
current European trials is not exhaustive; however, the purpose was to 
highlight some relevant examples to expose the ongoing paradigm shift 
towards prospective RTQA in clinical trials; and 3) Not all European countries 
responded to the international survey. Nonetheless, the inclusion of 21 
participating countries from all European regions (Northern, Western, Eastern 
and Southern/Mediterranean) allows to draw a rather comprehensive 
European perspective. 
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3.2. What is the dream? Identified areas of improvement 
 
The performed review and survey have helped identify the following 
areas of improvement. 
 
1. Standardization of treatment: Guidelines 
 
 Clinical guidelines are a useful tool and an affordable and 
straightforward approach towards standardization of treatments, especially for 
the management of highly complex diseases such as pediatric CNS tumors. 
This is particularly of importance for patients treated outside clinical trials. 
However, through our survey we found out that only 48% of the participating 
countries have national consensus guidelines for the treatment of pediatric 
CNS tumors.  
 National and/or international guidelines can be a first step to unify 
strategies, facilitate QA and improve the management of children with CNS 
tumors. Participation in frontline randomized clinical trials remain the standard 
treatment in pediatric oncology, but still, guidelines are often needed for 
aspects not covered in clinical trials or time periods where these are not open.  
 Moreover, almost all (91%) consulted experts believe that the patients 
would benefit to a considerable or to a great degree from a European RTQA 
guideline for pediatric brain tumors. There seems to be an increasing 
awareness of the necessity for a common effort across European CNS tumor 
specialists to ensure high-quality RT treatment for these complex patients. 
Looking at similar experiences in adult oncology, several international, 
disease-specific radiotherapy guidelines exist for adult cancers, based on 
published level 1 or 2 evidence and/or expert consensus, detailing delineation 
and dose recommendations for the specific disease (e.g. for glioblastoma 
[147, 148]. While level 1 or 2 evidence is not always available, especially in a 
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pediatric and rare disease context, consensus is certainly reachable. In parallel 
to generating consensus guidelines, regular audit procedures should be 
implemented at a local, national and international level to ensure the centers 
comply with the directives of the guidelines. This could raise the standards for 
RT treatment beyond clinical trial protocol provisions.  
 
2. Multidisciplinary work: Collaboration between pediatric oncologists and 
radiation oncologists 
 
 Multidisciplinary team work is essential for the treatment of pediatric 
CNS tumors. The importance of multidisciplinary tumor boards for pediatric 
tumors has been already reported [149, 150]; it is essential that radiation 
oncologists participate in these meetings. More concretely, a close and 
smooth interaction between pediatric oncologists and radiation oncologists is 
key to be able to implement new RTQA initiatives. In that regard, it is already a 
good sign that the answers we obtained from both types of specialists were 
similar. About two thirds (64%) of the consulted experts believe that the level 
of involvement of pediatric radiation oncologists in the meetings and activities 
of the respective national pediatric oncology societies is adequate (“somewhat 
sufficient” or “sufficient”). While this is a positive fact, it leaves room to 
improvement.  
Moreover, only one fifth (19%) of the participating countries have a 
national pediatric radiotherapy society. There might not be a need for 
independent societies, especially in small countries where the number of these 
specialists is low; but this is yet another reason to call for an increased  
involvement of radiation oncologists in the pediatric oncology societies and 
supranational initiatives. Beyond this, European platforms such as QUARTET 
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should be encouraged and strengthened with the incorporation of new 
members. 
  
3. Central storage of RT data 
 
As with other QA systems, an important component is the management 
of data. In that regard, an important step towards the implementation of wide 
RTQA systems is the central storage of RT data, which is currently done in 29% 
of the European countries according to our survey. An optimal storage should 
include the full planning and the final report, with the complete DICOM RT plan 
and any auxiliary imaging used to define the target(s); furthermore, all 
treatment deviations should be documented and stored as well. Following the 
Belgian example, an affordable first approach for this storage could be the use 
of the national cancer registries. The use of a shared database has the 
additional advantage of facilitating the link with other relevant clinical and 
translational data (long-term follow-up, biobanking, pathology reports, tumor 
genomics, etc.) while maintaining compliance with the new European Data 
Protection Regulation [151].  
While national registries and other initiatives such as the Dutch ProTraIT 
platform are excellent first steps, an international storage would have, without 
saying, many additional advantages. Additionally, the use of pan-European 
platforms would allow to include all types of pediatric patients with brain 
tumors, regardless of their inclusion in clinical trials. This would help to amplify 
our knowledge with real-world data, and eventually reduce the already 
mentioned gap between the outcome of patients enrolled in clinical trials 
versus the outcome of those treated outside that frame. 
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4. RTQA programs 
 
RTQA is an essential part of the treatment of pediatric brain tumors and, 
as such, it should be further developed, particularly at reference institutions. 
According to our survey, only one third (33%) of European countries have 
RTQA programs in place for the treatment of pediatric brain tumors; this is 
certainly a point to be improved across Europe. Additionally, the existing 
programs are heterogeneous, with different levels of complexity. 
A good start for the construction of RTQA programs is to implement 
systematic review systems of both, frontline and relapse RT plans. The ultimate 
aim is to have a prospective RTQA system in which each new RT plan is 
reviewed by an international expert panel before the treatment is applied to 
the patient, which is challenging due to time constraints in clinical practice. This 
is especially the case in children with brain tumors, in which the clinical situation 
may not allow delays in the start of the treatment, or in which it is already well 
proven that a late onset of RT reduces survival, such as the case of 
medulloblastoma [93]. This more ambitious approach of a prospective review 
is being currently implemented in some trials (e.g. SIOP-PNET 5, as already 
explained). However, until this can be extended across all types of CNS tumors 
and to patients treated outside clinical trials, the standards could be improved 
by a systematic continuous retrospective review.  
 
5. Equal access to RT for pediatric patients with CNS tumors across Europe  
 
 At a national level, no differences were reported in the access to RT 
treatment for children and adolescents with CNS tumors. The majority of 
experts participating in the survey (85%) agreed that this was the case in their 
respective countries. Additionally, two thirds (67%) believed that there was a 
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well-established national referral network for the RT treatment of pediatric 
patients.  
 As shown by several works in the literature, at a European level, 
inequality prevails [91, 152, 153]. There is a well-known inequality of outcomes 
for pediatric cancer patients across Europe [91]. One of the reasons could be 
the imbalance in radiotherapy, with a wide range of levels of access to best-
care facilities and specialists across European countries [92]. We have 
corroborated this with the findings in our survey: there is a wide variability in 
the number of public RT centers that treat pediatric patients with CNS tumors 
across countries, with some countries having 20 times more centers per million 
population than others. While the optimal number of centers is not established 
(and is probably in neither of both extremes), these data might possibly be 
another sign of inequality across Europe. 
A specific area which deserves attention is particle therapy, with fewer 
centers and less experience, and where indications, toxicities and long-term 
follow-up should be standardized. In this case, there is often already a 
centralized referral pathway, due to the scarcity of available facilities in each 
country, with almost all European countries (95%) granting access to PT within 
the public health system, according to the survey. However, this situation might 
change: According to the Particle Therapy Co-Operative Group (PTCOG), 
there are currently 75 particle therapy centers in operation, 41 centers under 
construction and 25 in planning stage all over the world [154]. Future work 
should include achieving international consensus for the indications of PT, as 
well as establishing appropriate studies and networks to manage and conduct 
long-term follow up for these patients.  
 
 Existing national and European referral networks for RT for pediatric 
brain tumors should be expanded and new ones created where none are 
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currently functioning. This is particularly relevant for complex radiation 
treatments. The recently launched European Reference Network for Pediatric 
Oncology (ERN PaedCan) [155] will be an appropriate framework in which to 
start implementing referral pathways for RT in pediatric brain tumors and 
promoting RTQA initiatives.  
 
In conclusion, RTQA understood as an ongoing audit of our medical 
practice, is essential in all aspects of pediatric oncology, but even more so in 
the highly technical and complex field of RT for CNS tumors. Several positive 
initiatives, both national and international, are being undertaken to implement 
RTQA in the treatment of pediatric patients across Europe, and there is still 
room for improvement. Creating a European RTQA guideline for pediatric CNS 
tumors, improving the collaboration between pediatric oncologists and 
radiation oncologists, building a European central storage system for RT data, 
implementing international RTQA platforms such as QUARTET, and promoting 
European referral networks to reduce inequality across countries are some of 
the measures that will hopefully contribute to improve the still dismal outcome 
of pediatric patients with CNS tumors and reduce long-term toxicities. 
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VI. DISCUSSION 
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Major advances in the treatment of pediatric cancers have been made 
over the last 40 years, turning a predominantly incurable disease into a disease 
with overall survival rates above 80% [6]. This has been mainly achieved 
through large international collaborative trials and multidisciplinary treatment. 
Furthermore, in this rare disease context, the enrollment of patients in frontline 
randomized clinical trials (RCTs) has become the standard treatment in 
pediatric oncology.  
However, international RCTs are not always accessible, for example for 
particularly rare tumors (such as CNS-PNETs) or for time periods between the 
opening of consecutive trials. Therefore, positive results obtained in RCTs 
should be reproducible in real-world settings, generating a genuine patient 
benefit across the globe. It is here where observational research plays a major 
role, be it with large population-based studies or with smaller, real-world 
patient cohorts, to investigate and corroborate the effects of new therapies or 
new strategies among patients treated in routine practice. As Booth et al. 
pointed out [156], observational studies are necessary and complementary to 
ensure that results of RCTs translate into benefits for the general population, 
that is, to demonstrate effectiveness. Ording et al. recently described some of 
the advantages of observational studies [157], namely the ability to investigate 
real-world safety issues (e.g. previously unrecognized concerns) by examining 
rare endpoints or multiple endpoints at once; the inclusion of real-world 
patients from clinical practice, such as frail patients with comorbidity that are 
usually excluded from clinical trials; and the possibility to examine the 
effectiveness of interventions applied in clinical practice and of long-term 
clinical outcomes, which are often not feasible to study in RCTs (Table 1).  
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Characteristics Clinical trials Observational studies 
Exposure 
- Intervention that may differ 
from clinical practice 
- Usually 1/2 interventions 
- Standard clinical practice 
- Any number of exposures 
Population Usually restricted (younger patients, no comorbidity, …) 
Can include entire patient 
populations 
Confounding 
control 
Randomization limits 
confounding 
Confounding by indication and 
unknown confounding is 
always a concern 
Compliance Measurable Difficult to measure 
Cost Expensive Inexpensive (registries) 
Time frame - Time consuming - Too short for rare endpoints 
- Often fast (if registries) 
- Feasible for rare endpoints 
Endpoints / 
Outcome 
- Standardized measure of 
endpoints 
- Blinding is possible 
- Restricted by routine clinical 
practice 
- No blinding 
 
 
TABLE 1 Characteristics of clinical trials versus observational studies. 
Adapted from Ording et al., 2016 [157] 
 
 Additionally, clinical audit is a key element of clinical governance and 
good medical practice. Regular auditing practice allows to explore whether 
treatment strategies are being optimally delivered [158, 159].  
A major goal of both, observational studies and clinical audits, is to 
ensure real benefit for patients, i.e. to close the gap between clinical trials and 
the real-world setting. This was precisely the global aim of this thesis, namely 
to combine the results of analyzing real-world cohorts of patients with data 
extracted through clinical audit tools in order to better understand the 
mentioned gap and to propose ways of reducing it. 
A good example of how dramatic the gap can be occurred when the 
HART-Milan strategy for metastatic medulloblastoma was generalized from a 
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single institution to a wider international setting, as reported by Vivekanandan 
et al. [29]. Gandola et al. reported a 77% 3-year OS in a single institutional 
cohort of patients with metastatic medulloblastoma, a considerable 
improvement in comparison with historical controls with 3-year OS of 40%.  
[28]. However, when the treatment strategy was implemented at a national 
level in the UK, the results obtained were far from the original, with a 3-year OS 
of 56% (95%CI: 38%-71%). Furthermore, severe cases of neurotoxicity, which 
were not observed in the original trial, were found in a separate UK cohort 
[160]. As a result of these real-world, observational studies, the HART-Milan 
strategy was abandoned in the UK and internationally, which accounts for the 
importance that these studies can have. 
 
Beyond this general problematic of clinical trials versus real-world 
settings and in spite of the improvements in the outcome of children and 
adolescents with CNS tumors over the last decades, mortality and morbidity 
rates remain unacceptably high. Hence, this group of diseases still constitutes 
a major challenge in pediatric oncology being one of the leading causes of 
death due to disease in childhood and a major cause of long-term disability [6, 
3]. 
To tackle this issue, several initiatives are currently being pursued by 
research groups all over the world, some of them particularly avant-garde and 
groundbreaking, to name a few: the advances in the knowledge of the tumor 
biology that have led to the discovery of four well-defined molecular 
subgroups of medulloblastoma and of new entities among the so called PNET 
group thanks to the new methods of molecular profiling (e.g. methylation and 
genomic profiling), which will soon change the way in which CNS tumors are 
diagnosed and classified [21, 62, 79]; the technological progress within the 
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classical treatment modalities, e.g. particle therapy, gamma-knife, and novel 
surgical techniques [124]; and the discovery of new drugs, especially with the 
uprising of targeted therapies and immunotherapy, which are paving the way 
towards Precision Medicine [43, 161, 162].  
While this is certainly an exciting era, it will take time and resources until 
all these advances are translated into real, tangible benefit for patients. In the 
meantime, in this wild race towards the top-notch therapies, we might be 
forgetting the basics: to optimize what we already have, auditing our current 
practices and developing tools to ensure the highest quality in the 
management of our patients are implemented across all pediatric oncology 
centers in Europe and globally. 
The aim of this thesis was to analyze the current multimodal 
management of children and adolescents with CNS tumors, to identify weak 
points and propose pragmatic measures that can improve the outcomes of 
patients at three levels: local, national and international. Three research 
projects were carried out to reach this objective. 
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Research Project #1: “Improving the quality of care in the molecular era for 
children and adolescents with medulloblastoma” 
 The aim of this study was to present a real-world cohort of children and 
adolescents with medulloblastoma, to search for weak points in their 
management that can be improved at a local/institutional level. We performed 
a monocentric review of all pediatric patients with medulloblastoma treated at 
Hospital Niño Jesús, Madrid, between 2003 and 2016. While we acknowledge 
some relevant limitations of the study due to its retrospective and monocentric 
nature, the derived conclusions are highly pragmatic and can be extrapolated 
to other institutions, ultimately improving the quality of care of the patients.  
The clinical audit revealed several areas of improvement, and we 
subsequently proposed a set of 27 quality indicators that may be used in the 
setup of a quality assurance system for the management of pediatric patients 
with CNS tumors. This implementation of a QA system is our first proposal to 
improve the outcomes of these patients. Other proposed measures include 
maximizing the inclusion of patients in international clinical trials, expanding 
the local Clinical Trials Unit, establishing a central pathology review, 
accelerating the translation of the new molecular knowledge into daily practice 
through the use of up-to-date biological markers, and implementing a 
neurocognitive and QOL evaluation program.  
These measures will hopefully improve the outcomes of children and 
adolescents with medulloblastoma in the near future, starting at a 
local/institutional level. 
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Research Project #2: “Management and outcome of children and adolescents 
with non-medulloblastoma CNS embryonal tumors in Spain: Room for 
improvement in standards of care” [101] 
 The two main aims of this study were to present a tumor-specific, 
national real-world data cohort (as opposed to clinical trials data) of children 
and adolescents with CNS-PNET/PB and to identify weak points and quality 
indicators that can be implemented to improve the still dismal outcome of 
these patients. The major interest in studying a tumor-specific cohort of PNET 
relies on the fact that, in addition to their low incidence and biological 
aggressiveness, these tumors have historically remained in the shadow of 
medulloblastoma, with a lack of specific approaches. 
We reviewed all pediatric patients with non-medulloblastoma CNS 
embryonal tumors treated in the eight major oncology centers in Spain 
between 2005 and 2014. We found a dismal outcome, especially when 
compared to patients included in clinical trials. Following our analysis, we 
proposed establishing a common national strategy, implementing referral 
circuits and collaboration networks, and incorporating new molecular 
knowledge into routine clinical practice as accessible measures that can 
improve the outcome of these patients.  
Furthermore, as a direct result of this study, a retrospective molecular 
analysis of archival tumor samples available for this patient cohort was started 
in collaboration with European reference centers; this will ultimately result as 
well in a benefit for children with this rare type of tumor. 
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Research Project #3: “Past, present and future of radiotherapy quality 
assurance in pediatric CNS tumors: A European perspective” 
The aim of this study was to present an overview of the situation of 
radiotherapy quality assurance of pediatric patients with brain tumors on an 
international level, and our perspective on the challenges of the future. To have 
this general perspective of the current situation, we analyzed past and current 
clinical trials protocols for pediatric CNS tumors and performed a survey about 
the practices of RTQA in pediatric CNS tumors across Europe with an “ask-the-
expert” approach. Pediatric oncologists and radiotherapists from 21 European 
countries participated. 
We found out that several positive initiatives, both national and 
international, are being taken to implement RTQA in the treatment of pediatric 
patients across Europe. However, there is still room for improvement, for which 
we proposed five key measures: Creating a European RTQA guideline for 
pediatric CNS tumors, improving the collaboration between pediatric 
oncologists and radiotherapists, building a European central storage system 
for RT data, implementing international RTQA platforms such as QUARTET, 
and promoting European referral networks to reduce inequality across 
countries. These measures may take years to be fully implemented, but they 
will hopefully contribute to improve the still dismal outcome of pediatric 
patients with CNS tumors. 
 
Overall, this thesis shows that there are several aspects to be improved 
in the management of pediatric patients with CNS tumors. Our set of proposed 
measures constitutes a pragmatic attempt to tackle the issue, with a three-level 
approach: local, national and international. Moreover, most of these measures 
transcend tumor-type specificity and hence could be applied across different 
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CNS tumors, particularly across embryonal tumors. We hope this work will 
contribute to the global improvement of survival and quality of life of children 
and adolescents with CNS tumors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement opportunities in the treatment of pediatric brain tumors - April 2018 
 
159 
VII. CONCLUSIONS 
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The conclusions from this thesis are listed below: 
 
Research Project #1: 
I) The global outcome of the real-world cohort of pediatric patients 
with medulloblastoma analyzed in this study is similar to the outcome 
observed in Spanish and European population-based studies.  
II) Several measures to improve the multidisciplinary management of 
pediatric patients with medulloblastoma have been proposed, and 
include implementing a quality assurance system, maximizing the 
inclusion in international clinical trials, expanding the local Clinical 
Trials Unit, establishing a central pathology review, accelerating the 
translation of the new molecular knowledge into daily practice 
through the use of up-to-date biological markers, and implementing 
a neurocognitive and QOL evaluation program.   
III) A set of 27 quality indicators to evaluate the management of 
pediatric patients with embryonal CNS tumors has been developed. 
Research Project #2: 
IV) Survival rates of the national, real-world cohort of pediatric patients 
with CNS-PNET have been lower than the rates in collaborative 
clinical trials. 
V) This study has served to identify specific aspects to improve in the 
care of patients with CNS-PNET, namely establishing a common 
national strategy, implementing referral networks, and incorporating 
new molecular knowledge into routine clinical practice. 
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VI) A retrospective molecular analysis of archival tumor samples 
available for this patient cohort has been started in collaboration with 
European reference centers, in an international ongoing study for 
diagnostic re-evaluation of CNS-PNET with methylation profiling. 
Research Project #3: 
VII) Initiatives to implement RTQA, both at national and international 
levels, are being developed to improve outcomes of the treatment 
of pediatric patients with CNS tumors across Europe. 
VIII) As a result of the analysis about the current practices of RTQA across 
Europe, five key measures were proposed: Creating a European 
RTQA guideline for pediatric CNS tumors, improving the 
collaboration between pediatric oncologists and radiation 
oncologists, building a European central storage system for RT data, 
implementing international RTQA platforms such as QUARTET, and 
promoting European referral networks to reduce inequality across 
countries. 
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CONCLUSIONES EN ESPAÑOL 
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Las conclusiones de esta tesis se enumeran a continuación:  
 
Proyecto de Investigación #1: 
I) La supervivencia global de la cohorte tipo “mundo real” de pacientes 
pediátricos con meduloblastoma analizada en este estudio es similar 
a la observada en estudios poblacionales españoles y europeos.  
II) Se proponen diversas medidas para mejorar el manejo 
multidisciplinar de los pacientes pediátricos con meduloblastoma: 
implementar un sistema de control de calidad, maximizar la inclusión 
en ensayos clínicos internacionales, expandir la Unidad de Ensayos 
Clínicos local, establecer una revisión central de la anatomía 
patológica, acelerar el traspaso del nuevo conocimiento molecular a 
la práctica clínica a través del uso de biomarcadores, e implementar 
un programa de evaluación de la función neurocognitiva y de la 
calidad de vida.   
III) Se ha desarrollado un set de 27 indicadores de calidad para evaluar 
el manejo de los pacientes pediátricos con tumores embrionarios 
del sistema nervioso central. 
Proyecto de Investigación #2: 
IV) Las tasas de supervivencia de la cohorte nacional tipo “mundo real” 
de pacientes pediátricos con tumores PNET del sistema nervioso 
central han resultado más bajas que las tasas observadas en ensayos 
clínicos colaborativos. 
V) Este estudio ha servido para identificar aspectos específicos a 
mejorar en el cuidado de los pacientes con tumores PNET del 
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sistema nervioso central, concretamente: establecer una estrategia 
nacional común, implementar redes de colaboración y centros de 
referencia, e incorporar el nuevo conocimiento molecular a la 
práctica clínica rutinaria. 
VI) Se ha iniciado un análisis molecular retrospectivo de las muestras 
tumorales de archivo disponibles para esta cohorte de pacientes, en 
colaboración con centros de referencia europeos, en un estudio 
internacional actualmente en marcha para la revaluación diagnóstica 
mediante perfil de metilación de los tumores PNET del sistema 
nervioso central. 
Proyecto de Investigación #3: 
VII) Se están desarrollando en Europa diversas iniciativas para 
implementar un sistema de control de calidad de la radioterapia 
tanto a nivel nacional como internacional, con el fin de mejorar los 
resultados del tratamiento de los pacientes pediátricos con tumores 
del sistema nervioso central.   
VIII) Como resultado del análisis sobre las prácticas de control de calidad 
de la radioterapia en Europa, se proponen cinco medidas clave: 
crear una guía europea para tumores pediátricos del sistema 
nervioso central, mejorar la colaboración entre oncólogos 
pediátricos y radio-oncólogos, construir un sistema central europeo 
de almacenaje de datos sobre radioterapia, implementar 
plataformas internacionales de control de calidad de la radioterapia 
(tales como QUARTET), y promover redes de colaboración y 
derivación europeas para disminuir la desigualdad entre países.  
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VIII. APPENDICES 
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Appendix 1 
Survey questionnaire: Current practices in radiotherapy for the 
treatment of pediatric patients with CNS tumors across Europe 
 
1. In your country: How many (public) centers treat pediatric patients with 
cancer? (Response: Number) 
2. In your country: How many (public) centers treat pediatric patients with 
brain tumors? (R: Number) 
3. In your country: How many (public) centers treat pediatric brain tumor 
patients with radiotherapy (excluding particle therapy)? (R: Number) 
4. What is your opinion regarding the following statement about 
radiotherapy in your country: “There is a known and well-established 
national referral network for the radiotherapy treatment of pediatric 
patients.” (R: Likert Scale with these five options: Strongly disagree – 
Disagree – Neutral – Agree – Strongly agree) 
#4: Please, provide a short explanation (R: Text. Not mandatory)  
5. Does your country have a national pediatric radio-oncologists society? 
(R: Yes/No) 
6. How would you qualify the level of involvement of pediatric radio-
oncologists in the meetings and activities of the national pediatric 
oncology society? (R: Likert Scale with these five options: Insufficient – 
Somewhat insufficient – Neither insufficient nor sufficient – Somewhat 
sufficient – Sufficient) 
#6: Please, provide a short explanation (R: Text. Not mandatory) 
7. Do national consensus guidelines exist in your country for the treatment 
of pediatric brain tumors? (R: Yes/No) 
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a. If Yes: Do they include RTQA (radiotherapy quality assurance) 
recommendations? (R: Yes/No) 
#7a: Please, provide a short description of the guideline(s) (R: 
Text. Not mandatory) 
8. Are you aware of any national (or local) radiotherapy quality assurance 
programs for the treatment of pediatric brain tumors? (R: Yes/No) 
a. If Yes: Please, indicate the name and provide a short description 
of the program(s) (R: Text) 
9. In your country: Is there a central storage system, such as a national 
registry for radiotherapy data? (R: Yes/No) 
a. If Yes: Are the complete DICOM radiotherapy plans collected as 
part of the data? (R: Yes/No) 
10. Do your patients have access to a particle therapy facility? (Nationwide 
or elsewhere, supported by the public health system) (R: Yes/No) 
#10: Please, provide a short explanation (R: Text. Not mandatory) 
11. Would you say that all pediatric patients with brain tumors in your 
country are granted equal access to radiotherapy? (R: Likert Scale with 
these five options: Strongly disagree – Disagree – Neutral – Agree – 
Strongly agree) 
#11: Please, provide a short explanation (R: Text. Not mandatory) 
12. Do you think that the patients would benefit from a European RTQA 
(radiotherapy quality assurance) guideline for pediatric brain tumors? 
(R: Likert Scale with these five options: Not at all – To a small degree – To 
a moderate degree – To a considerable degree – To a great degree) 
#12: Please, provide a short explanation (R: Text. Not mandatory) 
13. Comments (R: Text) 
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